{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6HiewIDA","lastupdate":"2024-01-08T00:00:00.000Z","update_date":"2024-01-08T00:00:00.000Z","lastModified":"Oct 29, 2025","active":1,"confidence_score":98,"confidence_score_reason":"video or image, markets","urlname":"kitov-pharmaceuticals","minimal_profile":null,"status":"Public","fullstatus":"Public on TASE on Jul, 2013;Public on NASDAQ on Nov, 2015;","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$25bRhdsVgwjsw5gGHwllY1Bhuh47gHfhNqXV6cabjGJHh5Ao4rQ1Dw","name":"Purple Biotech","oneliner":"Tumor-immune Evasion and Drug Resistance Therapies","registrar":"520031238","website":"https://purple-biotech.com/","careerspage":"","founded_month":8,"founded_year":1968,"formernames":["Kitov Pharmaceuticals"],"sociallinks":{"twitter":"https://twitter.com/kitov_pharma","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/6758085","instagram":""},"social":["https://twitter.com/kitov_pharma","https://www.linkedin.com/company/6758085"],"flattenedsociallinks":"https://twitter.com/kitov_pharma|https://www.linkedin.com/company/6758085","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"11-50","employees_exact":11,"patent":1,"raised":94600000,"stage":"Public","public_stage":"Public","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"Purple Biotech is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company’s oncology pipeline includes NT219, CM24 and IM1240. \n\n*NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. In a Phase 1/2 study of NT219, the Company is currently advancing it as a monotherapy treatment of solid tumors, and in a dose escalation in combination with cetuximab for the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck (SCCHN) or colorectal adenocarcinoma (CRC). These studies will be followed by an expansion phase of NT219 at its recommended Phase 2 level in combination with cetuximab in patients with recurrent and metastatic SCCHN. \n\n*CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways. The Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC). The Company has entered into a clinical collaboration agreement with Bristol Myers Squibb for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. \n\n*IM1240 is a preclinical, conditionally-activated tri-specific antibody that engages both T cells and NK cells to mount a strong, localized immune response within the tumor microenvironment. The third arm specifically targets the Tumor Associated Antigen (TAA) 5T4 that is expressed in a variety of solid tumors and is correlated with advanced disease, increased invasiveness and poor clinical outcomes. IM1240 has a cleavable capping technology that confines the compound’s therapeutic activity to the local tumor microenvironment, and thereby potentially increases the anticipated therapeutic window in patients. ","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97239333121","country":null,"address":{"israeli":[{"id":"94df5ded-152a-403f-baa6-93a6c4490324","city":"Rehovot","type":null,"address":"Rehovot, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"vCEgd5BURVyCyEqPa9xK7H9xppUSOl7HIUJhF6KjC6DHfypCkuG62p","date":"Oct 29, 2025","link":"https://finance.yahoo.com/news/purple-biotech-achieves-manufacturing-milestone-113300829.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"biotechnology","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd. has achieved a significant manufacturing milestone for its tri-specific antibody, IM1240, from the CAPTN-3 platform. This achievement validates the scalability of their technology, which targets tumor-associated antigen 5T4 and aims to overcome tumor immune evasion and drug resistance. The company plans to advance IM1240 towards first-in-human clinical trials with an IND submission planned for 2026. The CAPTN-3 platform is designed to engage both T cells and NK cells, inducing a strong localized immune response within the tumor microenvironment. This milestone positions Purple Biotech as a competitive player in developing complex tri-specific antibodies.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["antibody","tumor","immune","platform","clinical"],"date_of_event":"October 29, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"W4HXWB4nyfj5UKbDs2Umiy9SUlktARW156TIpt6tfj8a4EBNMwjgN6","news_summary":"Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"02LNy9Eo9VmmblspKzQ7Dzt6ZxsTqACw9l5FiXpCCr47BNSv4lqgED","date":"Sep 10, 2025","link":"https://finance.yahoo.com/news/purple-biotech-receives-intention-grant-120000657.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"patent, collaboration","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company, announced a significant development in its cancer treatment efforts. The European Patent Office intends to grant a patent for Purple Biotechs NT219 combinations with immunotherapies, which could enhance treatment responsiveness in resistant cancers. The patent, valid until 2036, covers combinations with immunotherapies like anti-PD-1 and MEK inhibitors. Purple Biotech is conducting a Phase 2 study in collaboration with the University of Colorado, evaluating NT219 with pembrolizumab and cetuximab for squamous cell carcinoma of the head and neck. The study aims to overcome tumor immune evasion and drug resistance, supported by preclinical data showing synergistic activity with immunotherapy.","partners":"University of Colorado","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["patent","immunotherapy","cancer","clinical trial","collaboration"],"date_of_event":"September 10, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"w4GoIgRjLF66q85Gso7aiL3RscKKs59aZKa1hioUnPD9WaPfL7HdDg","news_summary":"Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"88obO9LBoLtfZIqeyT0IjR5BSjPtQKq9ghbH3oG3DU4Uf4WEwKUthg","date":"Sep 9, 2025","link":"https://www.hotelmanagement-network.com/news/westin-desaru-coast-cayin-technology/","source":"www.hotelmanagement-network.com","visible":1,"analysis":{"tags":"partnership","round":null,"company":"CAYIN Technology","layoffs":null,"summary":"CAYIN Technology has partnered with Westin Desaru Coast Resort in Johor, Malaysia, to enhance guest communication and operational efficiency through the implementation of its CMS-WS server and CAYIN Signage Player. This collaboration involves the use of digital signage to provide real-time updates across 14 Samsung displays in various areas of the resort. The project was executed in partnership with Hola Media, which provided integration services, including installation, design, staff training, and support. The system has improved communication, reduced staff workload, and enhanced the guest experience, preparing the resort for future digital expansion.","partners":"Hola Media","customers":"Westin Desaru Coast Resort","eventType":null,"investors":null,"confidence":9,"key_topics":["partnership","digital signage","hospitality","operational efficiency","guest communication"],"date_of_event":"September 9, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"k5Yj1huWVlFrfm2vyUbW5Xdii8HGJfFMOA5dQmWEoZWmWtAWB7WTfO","news_summary":"Westin Desaru Coast Resort partners with CAYIN Technology for digital signage","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"i593rRbWNDThGlhqRE2CCnkRvIqxLFy33B1Yb4uBaQuz6Dm9y9uZ3D","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/nikkiso-addresses-growing-ammonia-handling-060000400.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"innovation","round":null,"company":"Nikkiso Clean Energy & Industrial Gases Group","layoffs":null,"summary":"Nikkiso Clean Energy & Industrial Gases Group (Nikkiso CE&IG) announced the launch of a next-generation submerged ammonia pump at the Gastech Conference. This pump is designed to be the safest and most reliable in the industry, addressing common maintenance issues with its seal-less, maintenance-friendly, copper-free construction. The pump can deliver over 2,500m3 per hour and has a mean time between outages of over 16,000 hours. This launch is part of Nikkiso CE&IGs ongoing innovation in ammonia handling, with the company having decades of experience in this field. The pump is expected to meet growing demand for ammonia in various sectors, including power generation and shipping.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["ammonia","pump","innovation","hydrogen","safety"],"date_of_event":"September 09, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2VNok2g511DpuYCdEJvslzcKzPSMNP5dIzmgMLw61kbxPaAtllRFpu","news_summary":"Nikkiso Addresses Growing Ammonia-Handling Demand and Launches Next-Generation Pump at Gastech 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"eauyqe0TurgOiTM6IbxciVRh6Ye4jdCZGFKavh25dmtF3ayrdnu5fv","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/assessing-valuation-yue-yuen-industrial-132603165.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"valuation","round":null,"company":"Yue Yuen Industrial (Holdings)","layoffs":null,"summary":"Yue Yuen Industrial (Holdings) has experienced notable stock price fluctuations, drawing attention from investors. Despite a year-to-date decline of 21%, the company has shown resilience with an 11% gain over the past year and a 13% increase in the past three months. Over a longer period, the stock is up 53% over three years and 44% over five years. The companys P/E ratio of 7.2x suggests it is undervalued compared to industry peers, indicating potential for growth if profit levels are sustained or improved. While the company shows steady revenue and net income growth, risks remain due to inconsistent short-term returns and potential shifts in market sentiment.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["valuation","P/E ratio","revenue","net income","market sentiment"],"date_of_event":null,"product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":"HK$31.84","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ZZ5MqWPMigsAF2WZxTCWp1KVxN3fB26lIrsev6vKIOuadMabmmAzqU","news_summary":"Assessing the Valuation of Yue Yuen Industrial (SEHK:551) After Recent Volatility","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"hMvMwOFy6U1mRSFhiOt502xNLDBchBMhWZFrVl6UgeCwb5cfhs3sFJ","date":"Sep 9, 2025","link":"https://sg.finance.yahoo.com/news/indian-stock-benchmarks-likely-open-023120091.html","source":"sg.finance.yahoo.com","visible":1,"analysis":{"tags":"share buyback","round":null,"company":"Infosys","layoffs":null,"summary":"Infosys led gains in Indias Nifty 50 index, which closed higher for the fifth consecutive session, driven by a 5% surge in Infosys shares following the announcement of a share buyback plan. The IT sector, which accounted for a significant portion of the days gains, benefited from expectations of a U.S. interest rate cut, which could boost technology spending in the U.S., a key market for Indian IT firms. The broader market also saw gains, with the Nifty 50 and BSE Sensex both rising by 0.39%. The anticipation of a Federal Reserve rate cut was fueled by weaker-than-expected U.S. job data.","partners":[],"customers":[],"eventType":null,"investors":[],"confidence":9,"key_topics":["Infosys","share buyback","IT stocks","U.S. rates","Nifty gains"],"date_of_event":"September 11","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"1rUiMkoKgpirdBPEjSGBxu0ebH5dLfoByYIpCDWEAdYVO5Xz61bcuc","news_summary":"Nifty clocks fifth session of gains led by IT on  Infosys buyback, US rate cut hopes","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"eGYcr9roaaDjzLfeq916KkBOoU7Cb0q5Gw725rlkaHPSAziBlEY2M8","date":"Sep 9, 2025","link":"https://finance.yahoo.com/news/bhp-xplor-opens-applications-2026-051100065.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"accelerator program","round":null,"company":"BHP Group Limited","layoffs":null,"summary":"BHP Group Limited has announced the opening of applications for the 2026 cohort of its BHP Xplor accelerator program, which aims to transform the discovery of critical minerals. The program offers early-stage explorers up to USD $500,000 in equity-free funding, mentorship, and access to BHP’s global network. BHP Xplor has been successful in previous years, fostering partnerships and accelerating exploration projects. The program supports BHPs long-term growth by engaging with diverse exploration projects. Applications are open from September 8 to October 15, 2025.","partners":["Electrum Discovery"],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["accelerator","exploration","minerals","funding","partnerships"],"date_of_event":"September 09, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"500,000","structured_issues":["Partners"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"JU8P5WAWgywLCNf6WRA537oGJ45YAIaSNJhWMadaGJs4wVk18MzFth","news_summary":"BHP Xplor Opens Applications for 2026 Cohort, Offering Equity-Free Funding and Global Support","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"axD0W2WVJ78TzDOoKumHDCk1wKZhgHIUL820o5dGvnMHMRnCUWYFc3","date":"Sep 5, 2025","link":"https://finance.yahoo.com/news/purple-biotech-announces-closing-18-200000564.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Public Offering","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company focused on developing oncology therapies, announced the closing of a public offering of 5,999,999 American Depositary Shares (ADSs) and short-term warrants to purchase up to 11,999,998 ADSs. The offering price was set at $1.00 per share, generating gross proceeds of approximately $6 million, with potential additional proceeds of $12 million if the warrants are fully exercised. H.C. Wainwright & Co. acted as the exclusive placement agent. The company plans to use the proceeds for the development of its oncology therapeutic candidates and general corporate purposes. The offering was conducted under a registration statement declared effective by the SEC on September 4, 2025.","partners":null,"customers":null,"eventType":"PO","investors":"H.C. Wainwright & Co.","confidence":10,"key_topics":["public offering","oncology","warrants","investment","development"],"date_of_event":"September 5, 2025","product_stage":"clinical trial","investment_date":"September 5, 2025","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$6 million","structured_issues":["PIPE/PO"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#PIPE/PO","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"k9AN4vNzRCXv27g6j6gY95S2P9Yr0HS3gEUDV76EUOsXKbxE6OrOim","news_summary":"Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"MIcQHG1CkM8Tp2OhDfdHUWnvTdSw6F5CDvlrdGBYwbCQcKxbFgbF1f","date":"Sep 4, 2025","link":"https://finance.yahoo.com/news/purple-biotech-announces-pricing-18-131500193.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Public Offering","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company focused on developing therapies to combat tumor immune evasion and drug resistance, announced a public offering of its American Depositary Shares (ADSs) and short-term warrants. The offering is expected to generate approximately $6 million in gross proceeds, with the potential for an additional $12 million if the short-term warrants are fully exercised. H.C. Wainwright & Co. is acting as the exclusive placement agent. The funds will be used for the development of oncology therapeutic candidates and general corporate purposes. The offering is made under a registration statement declared effective by the SEC, with the closing expected around September 5, 2025.","partners":null,"customers":null,"eventType":"PO","investors":"H.C. Wainwright & Co.","confidence":9,"key_topics":["Public Offering","Oncology","Therapeutics","Warrants","Investment"],"date_of_event":"September 4, 2025","product_stage":"clinical trial","investment_date":"September 4, 2025","acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"6 million","structured_issues":["PIPE/PO"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#PIPE/PO","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"yx68r149bQbJq5CjoZDg0gFhcp33xw6UBDHWoPW3oLKcdzqtj85NIC","news_summary":"Purple Biotech Announces Pricing of Up To $18 Million Public Offering","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"zVukujXhk7uBxz3cDI3vFeboIQlrPiOlrlkksrYP3To4kIeW3TvoJI","date":"Sep 4, 2025","link":"https://finance.yahoo.com/news/purple-biotech-announces-data-supporting-110000132.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company, has announced promising new data on its CAPTN-3 tri-specific antibody, IM1240, which targets the novel tumor-associated antigen 5T4. The research, conducted in collaboration with Dr. Amir Horowitz at the Icahn School of Medicine at Mount Sinai, demonstrates the antibodys potential to induce tumor cell death in treatment-resistant head and neck cancer biopsies. The study highlights the synergistic effects of the NK and T cell engager arms of IM1240, supporting its design and advancing it towards first-in-human clinical trials with an IND submission planned for 2026. This development is significant for Purple Biotech as it addresses unmet medical needs in cancers such as NSCLC and HNSCC.","partners":"Icahn School of Medicine at Mount Sinai","customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["IM1240","CAPTN-3","NKG2A","5T4","clinical trials"],"date_of_event":"September 4, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xqLvxresLq9N1QPJKENZ9D12ym1WCpo5Z7r0qPOo46cBQ9Yo5t4OsS","news_summary":"Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"J4iTArDO4jjrbq4uhaciIX6wWdaTmoJaxUuoCLzD3eGQEIgCVnE7ib","date":"Sep 3, 2025","link":"https://finance.yahoo.com/news/purple-biotech-expands-captn-3-110000450.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"innovation","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd. announced promising preclinical results for its tri-specific antibody, IM1305, targeting TROP2, a tumor-associated antigen. The antibody, part of the CAPTN-3 platform, has shown sustained tumor regression in a mouse model of triple-negative breast cancer. The CAPTN-3 platform activates both innate and adaptive immune systems, potentially overcoming the immunosuppressive tumor microenvironment. The company plans to submit an Investigational New Drug (IND) application by 2026 to advance IM1240 into first-in-human clinical trials. This development is part of Purple Biotechs strategy to expand its portfolio and leverage its technological advancements in targeting TROP2, a promising therapeutic target for various solid tumors.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["antibody","cancer","clinical trials","immune system","TROP2"],"date_of_event":"Sept. 03, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"PAMSM7nRmzLwNKEm8TuZqPJ4PzWXk1KBDA5uHPtFeWSBhz5D61byB7","news_summary":"Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"1Y7NPq2JYkkXfJcvMeHj8vGNQ2gtN3bV5eX2CgoVavsbhqAKIvrF8p","date":"Aug 27, 2025","link":"https://finance.yahoo.com/news/purple-biotech-participate-h-c-110000649.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"oncology, conference","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company focused on developing therapies to combat tumor immune evasion and drug resistance, announced its CEO, Gil Efron, will participate in the H.C. Wainwright 27th Annual Global Investment Conference. The company is advancing its oncology pipeline, which includes CAPTN-3, CM24, and NT219. CAPTN-3 is a preclinical platform of tri-specific antibodies designed to enhance immune response within the tumor microenvironment. CM24, a monoclonal antibody, has shown promise in a Phase 2 study for pancreatic ductal adenocarcinoma. NT219 is being tested in combination with cetuximab in a Phase 2 study. The conference participation is expected to enhance investor interest and visibility.","partners":"University of Colorado","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["clinical-stage","oncology","immune evasion","drug resistance","investment conference"],"date_of_event":"September 10, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Management Changes"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"1z0EPYne5MHs37HU9pyuW3sXXibkM5LuB57VqpROu9RIxANsAt1MlN","news_summary":"Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5RDa9MyFWB3KGruVy9peEaW7NfhaZkd08IOW59hZRCms6u3PWfLiMj","date":"Aug 6, 2025","link":"https://finance.yahoo.com/news/purple-biotech-reports-second-quarter-110000932.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trials","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company, is advancing its CAPTN-3 tri-specific antibody platform, which targets tumor-associated antigens, towards first-in-human clinical trials with an IND submission expected in 2026. The company reported positive Phase 2 data for its CM24 study in pancreatic ductal adenocarcinoma, showing significant efficacy in biomarker-enriched subgroups. Purple Biotech is seeking partners or investment to support the next phase of the CM24 study. The company is also focusing on advancing IM1240, its first CAPTN-3 antibody, through IND-enabling studies. Recent presentations at EACR and ASGCT 2025 highlighted the platforms potential in overcoming tumor immune evasion and drug resistance.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["CAPTN-3","CM24","clinical trials","antibody","biomarkers"],"date_of_event":"August 06, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners","Investment"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"b1YExQFRiGXzyUM3lfJulqKkYUAEswm278WVXiB6WPU8Gxygo73jgH","news_summary":"Purple Biotech Reports Second Quarter 2025 Financial Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ZLInysxmXrGPLJ5tFshyYnnjig5Ezpa4OG8d1nEmRcxaQouUSTsGwy","date":"Jul 23, 2025","link":"https://finance.yahoo.com/news/purple-biotech-ceo-issues-letter-110000627.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical progress","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company, reported significant scientific advancements in the first half of 2025. The company highlighted its progress in developing therapies to overcome tumor immune evasion and drug resistance. Key achievements include promising Phase 2 results for their CM24 monoclonal antibody, demonstrating strong objective response rates in biomarker-enriched subgroups of PDAC patients. Additionally, Purple Biotech presented data on their CAPTN-3 Tri-Specific Antibody Platform and initiated a Phase 2 study for NT219 in collaboration with the University of Colorado. These developments position the company for future growth and potential improved outcomes in biomarker-driven studies.","partners":["University of Colorado"],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["clinical trials","biomarkers","antibody therapy","tumor resistance","immune evasion"],"date_of_event":"July 23, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"qzlCrEUNrKPsCZV2OjRT4fvFtrWv1bXqrT164B1bF9KfRzV8XZjNgI","news_summary":"Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2ErABMisxgvfQ5qSiGR06uSFmMACcysC25bu0gDhUrJSJa5j2umQlF","date":"Jun 23, 2025","link":"https://finance.yahoo.com/news/purple-biotech-highlights-significant-advantages-110000661.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"innovation","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company, presented new preclinical data on its CAPTN-3 tri-specific antibody platform at the EACR 2025 Congress. The CAPTN-3 platform is designed to overcome tumor immune evasion and drug resistance by activating both the innate and adaptive immune systems. The platform includes an anti-NKG2A arm, which synergizes with the anti-CD3 arm to induce cytotoxic effects against solid tumor cells. The preclinical data demonstrate the potential of CAPTN-3 to re-invigorate exhausted T cells and efficiently kill tumor cells, highlighting the innovative design and potential therapeutic impact of the platform.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["CAPTN-3","antibodies","immune system","tumors","preclinical"],"date_of_event":"June 23, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xFHEGoHsLOXsV9wWIFMqmTP9lnXdRDMOOzcZPyfqVtgtVbT2H95LQP","news_summary":"Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"wOAavKswtqQNT771UC2PsdRa3Ad5Z0nuPdvoTEpN3sOGfPjIXqXlpv","date":"Jun 17, 2025","link":"https://finance.yahoo.com/news/purple-biotech-announces-initiation-phase-110000994.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd. announced the initiation of a Phase 2 clinical study for their novel small molecule, NT219, aimed at treating recurrent and/or metastatic squamous cell carcinoma of the head and neck. The study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus, will evaluate NT219 in combination with pembrolizumab or cetuximab. The study is structured into two single-arm cohorts and builds on promising Phase 1 results. The company aims to overcome tumor resistance and improve patient outcomes, marking a significant milestone in their clinical development efforts.","partners":"University of Colorado Anschutz Medical Campus","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["Phase 2","NT219","oncogenic pathways","tumor resistance","clinical study"],"date_of_event":"June 17, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"QkJ1QG4BCng1ZIenb03tWyDG8t9XXb5NPb1GDnkTW0oFjSwVesKrC3","news_summary":"Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"aOqAMrAKtFXShH7RgfysV9xT2RomoL5rBNYptyBgXK8oSy35HqSgKU","date":"Jun 4, 2025","link":"https://finance.yahoo.com/news/purple-biotech-announces-poster-presentation-110000539.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"immunotherapy","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company, is advancing its novel CAPTN-3 tri-specific antibody platform, which will be featured at the European Association for Cancer Research (EACR) 2025 Congress. The company is focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance. Its oncology pipeline includes CM24, NT219, and CAPTN-3, targeting various cancer indications. CM24 has shown promising results in a Phase 2 study for pancreatic ductal adenocarcinoma, while NT219 is advancing into a Phase 2 study for head and neck cancer. CAPTN-3 is in the preclinical stage, designed to engage T cells and NK cells to enhance immune response within the tumor microenvironment.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["clinical-stage","antibody platform","tumor immune","drug resistance","cancer research"],"date_of_event":"June 04, 2025","product_stage":"clinical","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"kkyLl1kgnIdfKGfQF6N86eLJ52HmygywYYo0pOCeB9UqDezKTGHMpa","news_summary":"Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ekGIOCqQszDTzppbfQw48nkRiY19dUYU4BX82pQmTjU88BfSLJiSWj","date":"May 21, 2025","link":"https://finance.yahoo.com/news/purple-biotech-reports-first-quarter-111000947.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trials","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company, presented promising data at the AACR Annual Meeting 2025, showcasing the final Phase 2 results for their CM24 study. The data demonstrated statistically significant efficacy in biomarker subgroup analyses, supporting the patient selection strategy for the upcoming Phase 2b study. Additionally, the NT219 Phase 2 study in head and neck cancer is on track to begin in the first half of 2025. The company is also advancing its CAPTN-3 platform towards first-in-human clinical trials. With a cash runway through mid-2026, Purple Biotech is well-positioned to continue its development of first-in-class therapies targeting tumor immune evasion and drug resistance.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["CM24","NT219","Phase 2","biomarkers","AACR"],"date_of_event":"May 21, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cAZycgf6PCBCGkYXkxShKDLQtR7N5gkvwU5YNCTdUozmPtMuVdzQpn","news_summary":"Purple Biotech Reports First Quarter 2025 Financial Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"BqIPB7stkHpYHufekLXIFc8Qf2awLlFFqttpQaP50DaLkAK1P2I0kz","date":"May 12, 2025","link":"https://finance.yahoo.com/news/purple-biotech-appoints-shai-lankry-113000542.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Management Changes","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company focused on developing therapies to overcome tumor immune evasion and drug resistance, announced the appointment of Shai Lankry as its new Chief Financial Officer. Lankry brings over 20 years of financial leadership experience in the biotech and healthcare sectors, including leading a U.S. IPO and M&A transactions. His appointment is seen as a strategic move to support Purple Biotechs growth and clinical development programs. The company is advancing its oncology pipeline, which includes CM24, NT219, and CAPTN-3, into late-stage trials with potential strategic partnerships. Purple Biotech is headquartered in Rehovot, Israel.","partners":["University of Colorado"],"customers":[],"eventType":null,"investors":[],"confidence":10,"key_topics":["biotech","oncology","clinical trials","management","immune therapy"],"date_of_event":"May 12, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"nJsPurmhqAaW2Oanutz9wEAnshCR3LMQ0w9e3G6laWhZX3GjToNRSQ","news_summary":"Purple Biotech Appoints Shai Lankry as Chief Financial Officer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"EYdk2jROS8HxjzMRHwJAVOEsg4BUStQWmPE9LZqDDlAgtBbo135QYG","date":"Apr 30, 2025","link":"https://finance.yahoo.com/news/purple-biotech-reports-final-data-110000531.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"biomarkers","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd. announced promising results from its Phase 2 study involving the drug CM24 in combination with nivolumab and chemotherapy for treating advanced pancreatic cancer. The study showed significant reductions in the risk of death and progression in specific biomarker subgroups, with up to a 90% reduction in risk of death. These findings were presented at the AACR 2025 meeting and suggest that CM24 could be a viable treatment option for cancers with large unmet needs. The company plans to use these biomarkers for patient selection in an upcoming Phase 2b study.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["biomarkers","pancreatic cancer","Phase 2 study","survival rates","AACR presentation"],"date_of_event":"April 30, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"tIPYGzVXJ9R1sx7aueGarYS9Ro9XkLxHQBfn6kPpWk1YTljMfETAdK","news_summary":"Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"A1bpGW3PzXi1Wc9A2RgLiPZEXxbcpl3TlyvmqaPtBRSr5Pi87POo9e","date":"Apr 28, 2025","link":"https://finance.yahoo.com/news/purple-biotech-reports-positive-nt219-122800847.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"biomarkers","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company, presented new data on NT219 at the AACR 2025 Annual Meeting. NT219 is a dual inhibitor being evaluated in a Phase 2 study for recurrent/metastatic head and neck squamous cell cancer (R/M HNSCC) in combination with pembrolizumab and cetuximab. The data highlights NT219s mechanism in suppressing immune evasion and tumor recurrence, with potential biomarkers identified for therapy in colorectal cancer. The findings support the ongoing Phase 2 study and suggest NT219s efficacy in combination therapies. The presentation at a prestigious conference underscores the promising developments in NT219s clinical evaluation.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["biomarkers","immunotherapy","cancer","clinical trial","NT219"],"date_of_event":"April 28, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UVZqODO3MXLEntg5tM78zlpblUIvPVQhwhrJjeRr7cS78WM7KDOnS1","news_summary":"Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"essNr0z6C8R69sarr5bRQU3ow3B910ODMF4sHBY7pXMUwwznK08IZt","date":"Apr 16, 2025","link":"https://finance.yahoo.com/news/purple-biotech-announces-publication-neuro-110000242.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"cancer research","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd. announced findings from a study showing that the combination therapy of NT219 and 5-fluorouracil (5-FU) inhibits brain metastasis in colorectal cancer through the IRS2 pathway. The study, conducted by researchers at Tel Aviv University and Sourasky Medical Center, identifies IRS2 as a driver of brain metastasis in colorectal cancer. The research suggests that targeting IRS2 with NT219 could be a powerful strategy to suppress brain metastasis and overcome chemo-resistance. Purple Biotech is advancing NT219 into a Phase 2 study for head and neck cancer and may expand its clinical development for colorectal and other cancers.","partners":["Tel Aviv University","Sourasky Medical Center"],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["colorectal cancer","brain metastasis","IRS2 pathway","combination therapy","clinical study"],"date_of_event":"April 16, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"VjbWKRH6q4UfGupD8jYdUJz3GBTOdOuggSswzbp29pmSw1AEEpd0GQ","news_summary":"Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"dIyevNyeRiaNiaz583EKMV0NtwNrZ4fLsbZ1l4VE3Nc6wXZ6TUsiNz","date":"Apr 1, 2025","link":"https://finance.yahoo.com/news/purple-biotech-participate-panel-discussion-110000350.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"oncology","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company based in Rehovot, Israel, is focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance. The company announced that its CEO, Gil Efron, will participate in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference. Purple Biotechs oncology pipeline includes CM24, NT219, and CAPTN-3, each targeting different aspects of cancer treatment. CM24 has shown promising results in a Phase 2 study for pancreatic ductal adenocarcinoma, while NT219 is advancing to a Phase 2 study for head and neck cancer. CAPTN-3 is in the preclinical stage, focusing on tri-specific antibodies. The companys efforts reflect a growth-positive trajectory in the oncology sector.","partners":"University of Colorado","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["oncology","therapies","immune evasion","drug resistance","clinical trials"],"date_of_event":"April 01, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Management Changes"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RWO44RlX0iwCLQYKvctBmraSyGNXNHItaHqFBz7NumAmLChyx8sHGR","news_summary":"Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"wry8ZmsdswM63WiF0ohJBPyxvbZH2HE7N3dm3p3gJkwgPt7UDvGxpc","date":"Mar 28, 2025","link":"https://finance.yahoo.com/news/purple-biotech-announces-three-posters-114500876.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"cancer research","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company, is advancing its oncology pipeline with promising therapies aimed at overcoming tumor immune evasion and drug resistance. The company announced upcoming presentations at the 2025 AACR Meeting, highlighting their work on CM24 and NT219 for treating various cancers. CM24, a humanized monoclonal antibody, has shown efficacy in a Phase 2 study for pancreatic cancer when combined with nivolumab and chemotherapy. NT219, a dual inhibitor, demonstrated anti-tumor activity in a Phase 1 study and is moving into Phase 2 trials in collaboration with the University of Colorado. Additionally, Purple Biotech is developing CAPTN-3, a preclinical platform of tri-specific antibodies targeting the tumor microenvironment. These advancements position Purple Biotech as a key player in innovative cancer treatments.","partners":"University of Colorado","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["cancer","biomarkers","antibodies","immune evasion","drug resistance"],"date_of_event":"March 28, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"hsaueQEKDCb4jnRCdoTQ7YivqyaobVEyrpnTnabtAevJNoB9BsLDyN","news_summary":"Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"NIRbSVZwt3vU0cQBu874HHVfqk7dpfpkSEp74Sbg878SHBbWR96LgR","date":"Mar 10, 2025","link":"https://finance.yahoo.com/news/purple-biotech-reports-fourth-quarter-125700752.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trials","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd. announced successful clinical trials for its oncology assets CM24 and NT219, demonstrating clinical benefits and identifying potential biomarkers. CM24 is set for a biomarker-driven Phase 2b study, while NT219 will proceed to a Phase 2 study in head and neck cancer in collaboration with the University of Colorado. The CAPTN-3 tri-specific platform shows promising preclinical data, positioning it well in the multi-specific antibody space. The company expects its cash runway to extend into mid-2026, allowing further progress on its ambitious programs. Purple Biotech collaborates with the Icahn School of Medicine at Mount Sinai to advance its CAPTN-3 platform.","partners":["University of Colorado","Icahn School of Medicine at Mount Sinai"],"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["clinical trials","oncology","biomarkers","collaboration","immunotherapy"],"date_of_event":"March 10, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"NLg1bLiABSe8IcIboIxmFkdPGq0bITJOY2f53bnr11OmEtHRiAvZvz","news_summary":"Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"MDOH0scUkkGXayiB1JXy2k4ojBQ5VESfsUWSnTeMro3h7NDK2G9nXI","date":"Mar 5, 2025","link":"https://finance.yahoo.com/news/purple-biotech-granted-u-patent-120000949.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"patent","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd. announced the issuance of a U.S. patent for NT219 in combination with EGFR antibodies, marking a significant milestone in their development of cancer therapies. NT219, a first-in-class small molecule drug, targets cancer resistance mechanisms and is currently in a Phase 2 study for head and neck cancer. The patent enhances Purple Biotechs intellectual property portfolio, providing geographic protection in major markets like the U.S., Europe, China, and Japan. This strengthens their position for potential commercialization. The company is also advancing other therapies, including CM24 and CAPTN-3, aimed at overcoming tumor immune evasion and drug resistance. Purple Biotechs headquarters are in Rehovot, Israel.","partners":"University of Colorado","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["patent","cancer","therapy","clinical trial","drug resistance"],"date_of_event":"March 05, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"developing","structuredIssuesShow":"#Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xG5x88WQLNOYzHuXWM6qQgpxvgs0m5gl2pjudUJWJRpOjyvWLSpBuo","news_summary":"Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ecRPrraXjMdbZW608ppAq0nIRJ6XcZzPv1YY48gpNm8iSCUDIw10pX","date":"Feb 18, 2025","link":"https://finance.yahoo.com/news/purple-biotech-advances-nt219-phase-120000411.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd. is advancing into a Phase 2 clinical trial with its novel agent NT219, designed to overcome tumor resistance in head and neck cancer treatments. The study, conducted in collaboration with the University of Colorado Anschutz Medical Campus, will evaluate NT219 in combination with pembrolizumab and cetuximab. The trial aims to assess the efficacy and safety of NT219 as a combination therapy, targeting key cancer resistance mechanisms. The market for treatments related to squamous cell carcinoma of the head and neck (SCCHN) is expected to grow significantly, highlighting the potential impact of NT219. The study will follow a Simon 2-stage design, initially enrolling 10 patients per arm, with an expansion cohort of 19 patients per arm.","partners":"University of Colorado Anschutz Medical Campus","customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["cancer","clinical trial","drug resistance","combination therapy","biomarkers"],"date_of_event":"February 18, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"44YBU72f712K6H8KIIUqpaI0Z30eMmePyCooatY9F2sMra20xWsObg","news_summary":"Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"SXB9A8ARd0PDD9VPTsIhtfi3ZphnXsxSatsAMm5sR4Ccm0t3NAvc7I","date":"Feb 3, 2025","link":"https://finance.yahoo.com/news/purple-biotech-announces-research-collaboration-120000171.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"immunotherapy","round":null,"company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company, has announced a research collaboration with the Icahn School of Medicine at Mount Sinai to explore the immunoregulation of NK and T cells within the tumor microenvironment using their CAPTN-3 multi-specific engagers. This collaboration aims to enhance tumor-specific immunity against various cancer types by targeting tumor-specific antigens and overcoming the limitations of current therapies. The study, led by Dr. Amir Horowitz, will focus on the modulation of HLA-E/NKG2A interactions and enhancing innate immunity features. This partnership is expected to advance the development of CAPTN-3 as Purple Biotech prepares for first-in-human clinical studies.","partners":["Icahn School of Medicine"],"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["immunoregulation","NK cells","T cells","tumor microenvironment","collaboration"],"date_of_event":"February 03, 2025","product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Product Stage"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Partners  #Product Stage","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xqXkHOLZnfz4SYgYYCFHJB7S3C1DGrlG7MljYZ8iJQpHM98ezdKTcd","news_summary":"Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"PDSbL1VsJrH8f9uvdEXIjnQzH166Ts0FvYGlNWauIK6bwSd0Hu0x2s","date":"Dec 5, 2024","link":"https://finance.yahoo.com/news/purple-biotech-announces-closing-2-121300698.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"investment","company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company focused on developing therapies to overcome tumor immune evasion and drug resistance, announced the closing of a registered direct offering of 472,668 American Depositary Shares (ADSs) at $6.00 per ADS. The offering, facilitated by H.C. Wainwright & Co. as the exclusive placement agent, raised approximately $2.8 million in gross proceeds. The funds will be used to advance the development of Purple Biotechs oncology therapeutic candidates and for general corporate purposes. The companys pipeline includes promising candidates like CM24, NT219, and IM1240, which are in various stages of clinical trials. The investment is expected to support ongoing research and development efforts, potentially leading to significant advancements in cancer treatment.","partners":null,"customers":null,"investors":"H.C. Wainwright & Co.","confidence":10,"key_topics":["oncology","therapies","investment","clinical trials","biotechnology"],"date_of_event":"December 5, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$2.8 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"UNZXtjmL4ULnTdmIHR0g4Y0WHcoZZdB9l7BqKRduDjM2uXhEtKbDMV","news_summary":"Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Ow3U06INbXSW8a20Go3DzniqEOYTPz7wVg0g9ED4j1eNfnyVkqfgzw","date":"Dec 3, 2024","link":"https://finance.yahoo.com/news/purple-biotech-announces-2-8-132300782.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"investment","company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company focused on developing therapies to overcome tumor immune evasion and drug resistance, announced a registered direct offering of its American Depositary Shares (ADSs). The company plans to sell 472,668 ADSs at $6.00 each, expecting gross proceeds of approximately $2.8 million. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The proceeds will be used to fund the development of Purple Biotechs oncology therapeutic candidates and for general corporate purposes. This investment is seen as a positive step for the company, supporting its ongoing research and development efforts in the oncology field.","partners":null,"customers":null,"investors":"H.C. Wainwright & Co.","confidence":10,"key_topics":["oncology","investment","therapies","immune","antibody"],"date_of_event":"December 3, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"2.8 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"mU6lFuldj182b9aSeZBzR5LNxehegC2vIHkyRqcKOlvia4PqzE2gzQ","news_summary":"Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ffIiINjbK2J89pfpN4iYEYN9q5lY6AAjDIOXKQqwLojDYvywwjgFjz","date":"Dec 2, 2024","link":"https://finance.yahoo.com/news/purple-biotech-reports-positive-final-120000926.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical trial","company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd. announced positive final results from a Phase 2 study of its lead oncology drug, CM24, in combination with nivolumab and standard chemotherapy for pancreatic ductal adenocarcinoma (PDAC). The study demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) in a biomarker-enriched patient population. The treatment arm showed a 79% reduction in the risk of death and a 90% reduction in the risk of progression or death compared to the control group. These promising results suggest CM24s potential as a treatment for multiple CEACAM1-expressing malignancies. A Phase 2b clinical study is planned to further explore these findings.","partners":"Bristol Myers Squibb","customers":null,"investors":null,"confidence":10,"key_topics":["CM24","efficacy","biomarkers","PDAC","nivolumab"],"date_of_event":"December 2, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oDLeWXKY7CabZmCENvdq2I3UEkzEFaB9g0n5u08XQ1aB1YDLj2xMy7","news_summary":"Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"g1egvNHMKHkZUJtV3w9xAkk5t68UDlmIJjPJbhH2XksCH1XKzdnkQe","date":"Nov 15, 2024","link":"https://finance.yahoo.com/news/purple-biotech-reports-third-quarter-120000614.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"biomarkers","company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd. announced promising developments in its Phase 2 CM24 pancreatic cancer trial, with topline data expected by the end of 2024. The company presented new biomarker data that could enhance patient outcomes by using serum biomarkers for patient selection. These findings were shared at the AACR Special Conference, highlighting the potential of CM24 as a CEACAM1 and NET targeted therapy. The company is advancing CM24 as a second-line treatment for pancreatic cancer and exploring other indications. Purple Biotechs financial results indicate a cash runway extending into Q4 2025, positioning them for potential partnerships. The recent data suggests improved overall survival for patients with high CEACAM1 and low PDL1 expression, supporting the CM24/nivolumab combined treatment.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["biomarkers","pancreatic cancer","clinical trials","CM24","immunotherapy"],"date_of_event":"November 15, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"LaZq6pum5WFT97DoBKRRem4UMTiFLxemLSrbglnVMsFqleCR1joC2u","news_summary":"Purple Biotech Reports Third Quarter 2024 Financial Results","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"riXqwnAkz7LWXLPXtNchoUDIelWjgvl3xL15AfyTugp6Ph89lSvR91","date":"Nov 5, 2024","link":"https://finance.yahoo.com/news/purple-biotech-unveils-promising-biomarker-131312523.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"biomarker discovery","company":"Purple Biotech","layoffs":null,"summary":"Purple Biotech has announced the identification of a new serum biomarker, CEACAM1, which could significantly enhance the effectiveness of their oncology therapeutic candidate, CM24, in treating metastatic pancreatic cancer. The discovery is part of ongoing Phase 2 trials and has shown promising results, with patients exhibiting a 79% reduction in the risk of death and improved survival rates when treated with CM24 in combination with chemotherapy. This breakthrough could lead to more personalized cancer treatments and improved patient outcomes, marking a positive development for Purple Biotech.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["biomarker","oncology","therapy","survival","trials"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"eqd9ax7xrACLgN6MjHZLAuWka2UY1vYHSmBjRbDXwUAtWuphhqmXLz","news_summary":"Purple Biotech Unveils Promising Biomarker for Cancer Therapy","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"y0Hy8gCtoj5YyaigbYKlafKQ4juAC88gp81JmBMmAxqYVKFo5R8D0h","date":"Nov 4, 2024","link":"https://finance.yahoo.com/news/purple-biotech-identifies-potential-serum-125000489.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"biomarker identification","company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd. announced the identification of serum CEACAM1 as a new potential blood biomarker for selecting metastatic pancreatic ductal adenocarcinoma (PDAC) patients likely to benefit from treatment with CM24. This discovery is part of a Phase 2 study evaluating CM24, a CEACAM1 inhibitor, in combination with nivolumab and chemotherapy. Patients with specific serum CEACAM1 levels showed improved progression-free and overall survival rates. The company is collaborating with Bristol Myers Squibb for these trials. The identification of this biomarker is seen as a significant advantage for future studies and potential cancer treatments. Purple Biotech is a clinical-stage company focused on developing therapies to overcome tumor immune evasion and drug resistance.","partners":["Bristol Myers Squibb"],"customers":null,"investors":null,"confidence":9,"key_topics":["biomarkers","pancreatic cancer","clinical trials","CM24","immunotherapy"],"date_of_event":"November 4, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Mc41SK1ZQKcfhG0mr4xYt0AyrB0l3agIk1zM85kgVLURSBuiguKnzE","news_summary":"Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Lxrhl3eaW3q83j7tZtwO7jFQUjHSB6vHH7wxInvnAp72UJnsGFb3o2","date":"Oct 25, 2024","link":"https://finance.yahoo.com/news/purple-biotech-presents-data-novel-112000823.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"cancer therapy","company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd. announced promising new data on its tri-specific antibody platform, CAPTN-3, at the EORTC-NCI-AACR Symposium. The platform demonstrated sustained tumor regression in a triple-negative breast cancer model and showed dose-dependent activity in non-small cell lung cancer explants. The lead tribody, IM1240, exhibited a preferred safety profile due to its conditionally activated capping technology. CAPTN-3s novel design engages T and NK cells to target tumors, offering a differentiated approach to cancer treatment. The platforms flexibility allows for the development of various antibodies to address different cancer types, potentially benefiting partners and patients. The company aims to reach first-in-human clinical studies with IM1240 by 2026.","partners":null,"customers":null,"investors":null,"confidence":10,"key_topics":["CAPTN-3","tribody","immune response","cancer","antibodies"],"date_of_event":"October 25, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"sRlmrIFXcxfA1wm629DqikqkgG0DqUUKBqWz4u4VijoYVnYlnNElmM","news_summary":"Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"0Syj46HBLIdAhiuyZqTU19H6yi0hjdRVARvbTNcurelUGvPhlji7XG","date":"Oct 11, 2024","link":"https://finance.yahoo.com/news/purple-biotech-unveils-captn-3-115721976.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"innovation","company":"Purple Biotech","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage biopharmaceutical company, is set to present its innovative CAPTN-3 platform at the EORTC-NCI-AACR Symposium. The CAPTN-3 technology employs a tri-specific antibody approach to activate T cells and NK cells, targeting the 5T4 antigen found in various solid tumors. This novel therapy aims to boost anti-tumor efficacy by inducing a strong localized immune response within the tumor microenvironment. The presentation of this groundbreaking technology is a significant step for Purple Biotech, potentially enhancing its reputation and growth prospects in the biopharmaceutical industry.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["CAPTN-3","antibody","immune response","tumors","EORTC-NCI-AACR"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"B4EWJJNWT11gQQk71RFKseY2H4uaIiMgvA43E6D14EMfdrBHquzG3D","news_summary":"Purple Biotech Unveils CAPTN-3 Cancer Therapy","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"mdEUOKXc38vMOu0dQEcMTa1nQM4wU6bpFb6y5O5TkoowTrLXAptA2Z","date":"Oct 10, 2024","link":"https://finance.yahoo.com/news/purple-biotech-present-data-tri-113000417.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"immunotherapy","company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company, has been selected for a poster presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The company will present its CAPTN-3 platform, a novel tri-specific antibody that engages T cells and NK cells to enhance anti-tumor efficacy. This platform targets the 5T4 tumor-associated antigen, which is overexpressed in various solid tumors. Purple Biotech is advancing its oncology pipeline, including CM24 and NT219, and has entered into a clinical collaboration with Bristol Myers Squibb for Phase 2 trials. The collaboration aims to evaluate the combination of CM24 with PD-1 inhibitor nivolumab and chemotherapy for treating pancreatic ductal adenocarcinoma. The event highlights Purple Biotechs innovative approach to cancer treatment and its strategic partnership with a major pharmaceutical company.","partners":["Bristol Myers Squibb"],"customers":null,"investors":null,"confidence":9,"key_topics":["immunotherapy","clinical trials","cancer treatment","antibody platform","collaboration"],"date_of_event":"October 23-25, 2024","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"3GENTjwOdQLq6ZJGfO1e599KMtOqAxdLvHRGTepGm39rZDn44BN5rF","news_summary":"Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"t07pIBJb4N0Nere2e4yNDqVGpeVmi3913SD9KH25TnYPHrt4PxNBp7","date":"Sep 18, 2024","link":"https://finance.yahoo.com/news/purple-biotech-reports-additional-positive-103000598.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"biomarker findings","company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd. reported new positive biomarker findings for its lead oncology therapeutic candidate CM24. The data, presented at the AACR Special Conference on Advances in Pancreatic Cancer Research, suggest that high CEACAM1 and low PDL1 expression in tumors are potential biomarkers associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) patients. The findings support the CM24/nivolumab combined treatment, showing potential for future biomarker-led studies. The Phase 2 study, conducted in collaboration with Bristol Myers Squibb, is evaluating CM24 in combination with nivolumab and standard chemotherapy. Interim data indicate improved overall survival and other efficacy endpoints. Topline data are expected in Q4 2024.","partners":["Bristol Myers Squibb"],"customers":[],"investors":[],"confidence":10,"key_topics":["biomarkers","survival","therapy","cancer","study"],"date_of_event":"2024-09-18","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RgzYrs9PaDrijmCqm5IsgOcEiBaQk0oPZqz2phtOx35e17FCABBGrJ","news_summary":"Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7kM9QNAHmN9x8ZhkVFSUZ8HUQWC4088sWQfDHpWnnWOnvvGhNW1M48","date":"Sep 16, 2024","link":"https://finance.yahoo.com/news/upcoming-stock-splits-week-september-133837938.html","source":"finance.yahoo.com","visible":1,"analysis":{"date":"Wed Sep 25 2024","status":-1,"message":"Unexpected token ` in JSON at position 926","entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"jEfPiMFXLl94XHDQXzqJ30KzwDjf7N8OBcqhOYjw63kUAhO1L8dQiO","news_summary":"Upcoming Stock Splits This Week (September 16 to September 20) – Stay Invested","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"CsEGtSOOep44XOPTVVwtm3p3nb5Sjjl0CE2DV5VLdMOV0FK6WbYXEi","date":"Sep 10, 2024","link":"https://finance.yahoo.com/news/purple-biotech-present-data-lead-110000362.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"clinical-trial","company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd. announced its selection for a poster presentation at the AACR Special Conference on Advances in Pancreatic Cancer Research, to be held from September 15-18, 2024, in Boston. The companys Phase 2 study evaluates CM24 in combination with Bristol Myers Squibbs PD-1 inhibitor nivolumab and standard chemotherapy in advanced pancreatic cancer patients. Interim data showed improved overall survival and other efficacy endpoints. The company has a clinical collaboration with Bristol Myers Squibb for this trial. Topline data are expected in Q4 2024.","partners":["Bristol Myers Squibb"],"customers":["patients in the U.S., Spain, and Israel"],"investors":[],"confidence":10,"key_topics":["Phase 2","Pancreatic Cancer","CM24","Nivolumab","Chemotherapy"],"date_of_event":"2024-09-10","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"NYefZkHndAdTc5PfwwwCiGwGehHKAdxHWcosBYDRDyUs1RJMzcXGvO","news_summary":"Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"GY9IcvieC4Lrce5pQU94NVP43L03CfocNuSxDvcDbd2lxzAUclWJLP","date":"Aug 30, 2024","link":"https://finance.yahoo.com/news/purple-biotech-participate-h-c-110000066.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"investment conference","company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd., a clinical-stage company focused on developing therapies to overcome tumor immune evasion and drug resistance, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will be held virtually and in-person from September 9-11, 2024. CEO Gil Efron will present a Fireside Chat and conduct one-on-one meetings with institutional investors. Purple Biotech is advancing several oncology therapies, including CM24, NT219, and IM1240, and has a clinical collaboration with Bristol Myers Squibb for Phase 2 trials. The companys headquarters are in Rehovot, Israel.","partners":["Bristol Myers Squibb"],"customers":null,"investors":[],"confidence":10,"key_topics":["conference","clinical trials","partnership","oncology","investment"],"date_of_event":"2024-09-09","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"zvkKYDdMRtXm3v8ESq00tFssyM2WcZp3Thgx0pcLpgTfxHb4uzXsuI","news_summary":"Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"TKJXf8h26cWuloG0juAn1o9YS07eJjuza0EcycSTRqFiI1QS9OaLew","date":"Aug 16, 2024","link":"https://finance.yahoo.com/news/purple-biotech-reports-second-quarter-121200917.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Trials, Financial Results","company":"Purple Biotech Ltd.","layoffs":"33% reduction in workforce","summary":"Purple Biotech Ltd. has reported positive interim data from its Phase 2 CM24 pancreatic cancer study at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. The data shows improvement in overall survival, progression free survival, objective response rate and all other efficacy endpoints. The company is considering expanding the CM24 clinical program to a biomarker driven study in additional indications. The company also announced its financial results for the three and six months ended June 30, 2024, showing a decrease in R&D expenses and an increase in financial income related to changes in fair value of warrants. The company has extended its cash runway to Q3 2025.","partners":"Bristol Myers Squibb","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Clinical Trial Results","Financial Results","Management Changes","Layoffs","Investment"],"date_of_event":"Aug. 16, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Management Changes","Layoffs"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Management Changes  #Layoffs","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Wne3VBB9jdKORpB4XZA6KajwLOnVONUeo0C536S10Fs4Wb4xx3aeww","news_summary":"Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"cmi39NsT8V26BcQERfHCBILSgUqprokhbqyNb3lSAuwIAYQ9PhvkzQ","date":"Jul 25, 2024","link":"https://finance.yahoo.com/news/purple-biotech-receives-extension-regain-113500786.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Compliance, Stock Market","company":"Purple Biotech Ltd.","layoffs":"N/A","summary":"Purple Biotech Ltd., a clinical-stage company developing oncology therapies, has received a 180-day extension from the Nasdaq Stock Market to regain compliance with the minimum $1.00 bid price requirement for continued listing. The company now has until January 21, 2025, to regain compliance. The receipt of the extension period has no immediate effect on the listing or trading of the companys ADSs, which will continue to be listed and traded on the Nasdaq Capital Market under the symbol PPBT.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Nasdaq Compliance","Oncology Therapies","Bid Price Requirement","Extension Period","Clinical-stage Company"],"date_of_event":"July 25, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Public Trading","acquisition_amount":"N/A","structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"DCH9Li6DY9zsZGRbJPEwCOcTjr5YLD9YMuPXGFIhGRThqBcmMAliig","news_summary":"Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"X7XxbVZP8WYa0zt8cVOB5Pkw9bq6nk4528mjtouEwUbVKJ9UIXHM4G","date":"Jul 10, 2024","link":"https://finance.yahoo.com/news/purple-biotech-host-virtual-kol-113000435.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Oncology Therapies, Clinical Trials","company":"Purple Biotech Ltd.","layoffs":"N/A","summary":"Purple Biotech Ltd., a clinical-stage company developing oncology therapies, has announced further details on its virtual key opinion leader event. The event will feature Michael Cecchini, MD (Yale School of Medicine) and E. Gabriela Chiorean, MD, FASCO (University of Washington School of Medicine, Fred Hutchinson Cancer Center), who will discuss the positive interim data from the Phase 2 study of CM24. The event will also focus on data reported at the 2024 ASCO Annual Meeting. The company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC).","partners":"Bristol Myers Squibb","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Clinical Trials","Oncology Therapies","Partnership","Management","Research"],"date_of_event":"July 10, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Partners","Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Partners  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"TtNlc9ECOYPd1AKDTXpEvOEAIWh5oRB1KBTQtGNRuOiIHcGm0ku7cy","news_summary":"Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Cfa3Yl7uMzfwLF0xRKyGJ5nTdK3oVcstZOfVD9lUhUI8bxtfaEcsKO","date":"Jul 2, 2024","link":"https://finance.yahoo.com/news/purple-biotech-announces-closing-exercise-200000831.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investment, Expansion","company":"Purple Biotech Ltd.","layoffs":"Not mentioned","summary":"Purple Biotech Ltd., a clinical-stage company developing first-in-class therapies for tumor immune evasion and drug resistance, has announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 5,633,509 American Depositary Shares (ADSs). The gross proceeds from the exercise of the existing warrants were approximately $2 million. The company intends to use the net proceeds from the offering to fund the development of its oncology therapeutic candidates and for general working capital and corporate purposes.","partners":"Bristol Myers Squibb","customers":"Not mentioned","investors":"H.C. Wainwright & Co.","confidence":9,"key_topics":["Investment","Oncology Therapeutic Candidates","Warrants Exercise","Clinical-stage Company","Drug Development"],"date_of_event":"July 02, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$2 million","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"SxJ4uVBUMGEyRKyzTs4IzaRIw47U0xQcdcmSH1n6g5YQXQZChJaiHi","news_summary":"Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"RLxvC0QJHYiR9itKsXYUwkxPUAJHqMSkby9F73c6iDQ8K0c0Oif5mD","date":"Jul 1, 2024","link":"https://finance.yahoo.com/news/purple-biotech-announces-exercise-warrants-130000196.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Investment, Oncology","company":"Purple Biotech Ltd.","layoffs":"Not mentioned","summary":"Purple Biotech Ltd. has announced definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 5,633,509 American Depositary Shares (ADSs). The gross proceeds from the exercise of the existing warrants are expected to be approximately $2 million. The company intends to use the net proceeds from the offering to fund the development of its oncology therapeutic candidates and for general working capital and corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.","partners":"Not mentioned","customers":"Not mentioned","investors":"H.C. Wainwright & Co.","confidence":9,"key_topics":["Warrant Exercise","Oncology Therapeutic Candidates","Private Placement","Securities Act","Future Plans"],"date_of_event":"July 01, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$2 million","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"tTBtDMtGM18T5ArkupNV8y8h6R2AhPNb5HQyl233DPma8XyoeRCvS8","news_summary":"Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"qo9n90EwQdfcgXmWUbIsnwE0I7REa70pq5aL0P6iO2BcOINLoE7gG4","date":"Jun 27, 2024","link":"https://finance.yahoo.com/news/purple-biotech-reports-additional-positive-114500979.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Trials, Oncology","company":"Purple Biotech Ltd.","layoffs":"N/A","summary":"Purple Biotech Ltd. has reported positive interim data from its Phase 2 study of CM24, a treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). The study, conducted in partnership with Bristol Myers Squibb, found that patients treated with CM24 in combination with nivolumab and standard of care (SoC) chemotherapy showed a reduction in risk of death and cancer progression, as well as improved overall survival and progression free survival. The company also identified serum myeloperoxidase (MPO) as a potential predictive biomarker for survival. Further data and results are expected in the second half of 2024.","partners":"Bristol Myers Squibb","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Clinical Trials","Oncology","Cancer Treatment","Biomarker Data","Partnership"],"date_of_event":"June 27, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Investment","Partners"],"acquisition_amount":"N/A","structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"mPkiUoeOpQad56yVXTdHW3FvE4yCan6kth2MENpFHpYN0mMRMSCH1z","news_summary":"Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"eBVDrTL2tiB8akK7roZNF7nenXmFufAOMHyLPLmFiDwtaKyfCcRyhn","date":"Jun 1, 2024","link":"https://finance.yahoo.com/news/purple-biotech-announces-positive-breaking-120000552.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Trials, Cancer Treatment","company":"Purple Biotech Ltd.","layoffs":"Not mentioned","summary":"Purple Biotech Ltd. has announced positive interim data from its Phase 2 study of CM24 in second-line metastatic pancreatic ductal adenocarcinoma (PDAC). The data shows a 26% reduction in risk of death and a 28% risk reduction in progression or death in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care. The study is evaluating CM24, a novel first-in-class multi-functional anti-CEACAM1 antibody, in combination with Bristol Myers Squibb’s immune checkpoint inhibitor nivolumab plus SoC chemotherapy in second-line PDAC patients versus SoC chemotherapy alone. The interim data was presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.","partners":"Bristol Myers Squibb","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Clinical Trials","Cancer Treatment","Interim Data","Pancreatic Cancer","Chemotherapy"],"date_of_event":"June 01, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HGHpabAEUyPgqUM0Sklee8pHzYIIHW9AWRny2qa7C0pBFQD8tR38Cp","news_summary":"Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"nJqSUU4trrKp9Vxh7tVq89MrP83j3FD20RpPK9AvE7kQ53cetc8oWU","date":"May 21, 2024","link":"https://finance.yahoo.com/news/purple-biotech-reports-first-quarter-113000202.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Trials, Financial Results","company":"Purple Biotech Ltd.","layoffs":"Not mentioned","summary":"Purple Biotech Ltd. has announced its financial results for the first quarter of 2024, along with updates on its clinical trials. The company is developing therapies for cancer and has been selected to present interim Phase 2 data for the treatment of pancreatic cancer at ASCO 2024. The company also reported a decrease in operating loss and net loss for the quarter, compared to the same period in 2023. Purple Biotech also sold approximately 504,000 ADSs under the Open Market Sale AgreementSM with Jefferies LLC, netting approximately $358,000.","partners":"Bristol Myers Squibb","customers":"Not mentioned","investors":"Jefferies LLC","confidence":9,"key_topics":["Clinical Trials","Financial Results","Cancer Treatment","Drug Development","Investment"],"date_of_event":"May 21, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$358,000","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ieYD9hMsp5Xmk6fe0CLkZ4elN2jSFYWlxJQv5BIy2XOZ8x82yozlpw","news_summary":"Purple Biotech Reports First Quarter 2024 Financial Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"sM4FIa0U4eQLMopDzX9UzBy3s6eTRJQh4ELBV3cKZuEVpfu5nsqPjT","date":"Apr 25, 2024","link":"https://finance.yahoo.com/news/purple-biotechs-randomized-phase-2-110000846.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Trials, Cancer Treatment","company":"Purple Biotech Ltd.","layoffs":"N/A","summary":"Purple Biotech Ltd. has announced interim results from its Phase 2 study of CM24, a first in class immune checkpoint inhibitor, for the treatment of pancreatic ductal adenocarcinoma (PDAC). The data suggests a reduced risk of progression or death in the experimental arm of the study. The study is being conducted in collaboration with Bristol Myers Squibb (BMS) and the results will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The company retains all worldwide rights to CM24.","partners":"Bristol Myers Squibb","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Clinical Study","Cancer Treatment","ASCO Meeting","Interim Results","Partnership"],"date_of_event":"April 25, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Partners"],"acquisition_amount":"N/A","structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"mWBNfewh3jg0oJvi1Ez4XiVa7aPHJCO1jDg5YIanraFoNTfciqdakn","news_summary":"Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8Oci7XHZpwC0M2ltrEXisHQzBbLN1XVcVgCHcBp1QHHJkjWUlWutsC","date":"Mar 28, 2024","link":"https://finance.yahoo.com/news/purple-biotech-present-data-oncology-110000385.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Cancer Research, Drug Development","company":"Purple Biotech Ltd.","layoffs":"Not mentioned","summary":"Purple Biotech Ltd. announced it will present data for its oncology candidate NT219 at the American Association for Cancer Research (AACR) annual meeting. The data shows NT219s potential in suppressing cancer stem cells that promote drug resistance and tumor recurrence. The company also identified potential biomarkers for treatment with NT219 in responding patients in Phase 1. The companys CEO, Gil Efron, expressed optimism about leveraging these data as they move forward with the clinical evaluation of NT219.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Cancer Treatment","Drug Resistance","Clinical Trials","Biomarkers","Tumor Microenvironment"],"date_of_event":"March 28, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8J97gb57Tf2yiwdM6kBGPVhZrRspUNLjqYGpACDhdmSFQy550W14Tn","news_summary":"Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"xKF36sGdrZufEm1FyFJAqdRrwqGacGArN8g66PKntqRMWangaqjL4P","date":"Mar 14, 2024","link":"https://finance.yahoo.com/news/purple-biotech-reports-preclinical-proof-113000309.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Cancer Treatment, Clinical Trials","company":"Purple Biotech Ltd.","layoffs":"Not mentioned","summary":"Purple Biotech Ltd., a clinical-stage company, has reported preclinical proof of concept data for its conditionally-activated tri-specific antibody platform. The platform engages both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The companys cleavable capping technology confines the compound’s therapeutic activity to the local tumor micro environment, potentially increasing the anticipated therapeutic window in patients. The companys oncology pipeline includes NT219, CM24 and IM1240.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"Cancer Treatment, Clinical Trials, Drug Development, Biotech, Oncology","date_of_event":"March 14, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"aYyQkWGaUT9yWPQVNniKcKPnnHV27njhvCqpZ3cGXpvad7H5tcKjF0","news_summary":"Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d5mIYONz0aeM9efp068r90JGWequKfVEeVlplZZfZvWPqczMY8U9UI","date":"Mar 5, 2024","link":"https://finance.yahoo.com/news/purple-biotech-reports-fourth-quarter-125500426.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Results, Clinical Progress","company":"Purple Biotech Ltd.","layoffs":"Not mentioned","summary":"Purple Biotech Ltd., a clinical-stage company developing first-in-class therapies for cancer, announced its financial results for the fourth quarter and full year ended December 31, 2023. The company made significant clinical progress with its two lead oncology candidates, CM24 and NT219, positioning them as potential second line treatments for pancreatic and head and neck cancer. The company also acquired a platform of conditionally activated T cells and NK cell engagers last year, which has strengthened its approach to cancer treatment. The companys cash position provides a cash runway into the first half of 2025.","partners":"Bristol Myers Squibb","customers":"Not mentioned","investors":"Jefferies LLC","confidence":10,"key_topics":["Financial Results","Clinical Trials","Acquisition","Cancer Treatment","Investment"],"date_of_event":"March 05, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Acquisition","Management Changes"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Acquisition  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"PTW6yfNvYEmUmYLjkriRHk3aJT2Gt9YkKmVZ7jHkk7R4IGm3GEuybS","news_summary":"Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"J6s45YHeuItPKZx0OieArj1kYuUnsRq2UVf6Bobpl8hND4RRsO7DEG","date":"Feb 27, 2024","link":"https://finance.yahoo.com/news/purple-biotech-presents-data-phase-120000569.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Trials, Cancer Treatment","company":"Purple Biotech Ltd.","layoffs":"N/A","summary":"Purple Biotech Ltd. has announced positive clinical results from its Phase 1/2 dose escalation study of NT219 in combination with cetuximab in the treatment of patients with recurrent/metastatic head and neck cancer. The data was presented at the European Society of Medical Oncology Targeted Anticancer Therapies Congress 2024. The study showed that NT219 was well tolerated and demonstrated anti-tumor activity. The company plans to initiate a Phase 2 study in combination with cetuximab in head and neck cancer in the first half of 2024.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Clinical Results","NT219","Cancer Treatment","Phase 1/2 Study","Future Plans"],"date_of_event":"Feb. 27, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Investment","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"LyzlVo1GegekZUKonMTjgtdK4aTj4eY5ZhEAidTxvssHLhsYZFtSfo","news_summary":"Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"wvdkwmylJqKd9ZuqfdnRbjmIQs96QHAwKvPA1vhJwSMfyEVeXvuKhT","date":"Feb 13, 2024","link":"https://finance.yahoo.com/news/purple-biotech-convenes-head-neck-120000259.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Trials, Cancer Treatment","company":"Purple Biotech Ltd.","layoffs":"N/A","summary":"Purple Biotech Ltd. has convened a Scientific Advisory Board (SAB) to focus on the use of NT219 in the treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The SAB, comprised of oncologists, researchers, and investigators, provided insights on the therapeutic landscape of R/M SCCHN treatment and guidance on clinical studies for NT219. The company has determined the recommended Phase 2 dose and is prepared to move to the next phase of development. Purple Biotech is a clinical-stage company developing therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["NT219","Head and Neck Cancer","Clinical Trials","Scientific Advisory Board","Drug Resistance"],"date_of_event":"Feb. 13, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Management Changes","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"o5ZYN00ocG5KYkrfsJwi7DDlx6FJzM5YYqEjuNQcELcZgewT4YXEhm","news_summary":"Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0WyZ2goImTmpFCfWl75Bh8hb8O1R2Bqm7CQpRvM7IzHSLRFhDUC9Jz","date":"Feb 1, 2024","link":"https://finance.yahoo.com/news/purple-biotech-reaches-recommended-phase-123000838.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Drug Development, Cancer Treatment","company":"Purple Biotech Ltd.","layoffs":"Not mentioned","summary":"Purple Biotech Ltd. has announced the recommended Phase 2 dose for NT219, a first-in-class small molecule dual inhibitor, in combination with cetuximab for the treatment of head and neck cancer. The dose was determined based on data from a Phase 1/2 dose escalation study. The company reported that NT219, in combination with cetuximab, demonstrated a dose-dependent anti-tumor activity with confirmed partial responses. The company is now advancing its upcoming Phase 2 Proof of Concept study of NT219 for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"NT219, Phase 2, Cetuximab, Head and Neck Cancer, Clinical Trials","date_of_event":"Feb. 01, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"U8Z1enFtFl8fevwzRp6JlYkzU5FwOhEyL8Z3kTs6msIa1JlLA1GcKt","news_summary":"Purple Biotech Reaches Recommended Phase 2 Dose for NT219","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"KbuDJfMN7P7fcAoeDywN8z99UahdczsU4XIDetcEM7auj577xidDNY","date":"Dec 20, 2023","link":"https://finance.yahoo.com/news/purple-biotech-appoints-dr-yael-130500355.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Management Changes","company":"Purple Biotech Ltd.","layoffs":"N/A","summary":"Purple Biotech Ltd. has announced the appointment of Dr. Yael Margolin as an independent member of the companys Board of Directors. Dr. Margolin brings over 35 years of experience in biotechnology, pharma, and venture capital. The company also announced the resignation of Mr. Fabien Sebille, who served as the Company’s Chief Business Officer. Purple Biotech is a clinical-stage company developing therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":10,"key_topics":["Board Appointment","Resignation"],"date_of_event":"Dec. 20, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"EmdQ9RP5iZb2KyhGTway8aIypobP3su61OkLvEfln4QikoyrgM3Aqv","news_summary":"Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7vqUfTH35yLCKdIMM81xaeZLAj4ovBDuZHZTSZwNCQwgJkO2yjHGbR","date":"Dec 14, 2023","link":"https://finance.yahoo.com/news/purple-biotech-completes-patient-enrollment-115000983.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Trials, Drug Development","company":"Purple Biotech Ltd.","layoffs":"N/A","summary":"Purple Biotech Ltd. has completed patient enrollment in a Phase 2 study of CM24, a multi-functional immune checkpoint inhibitor, for the treatment of pancreatic ductal adenocarcinoma (PDAC). The study, in collaboration with Bristol Myers Squibb (BMS), is evaluating CM24 in combination with BMS’s nivolumab plus chemotherapy in PDAC patients. The trial was fully enrolled in advance of the anticipated 2024 timeline. An interim analysis of overall survival, the primary endpoint of the study is expected during 1H 2024 and topline analysis is expected in 2H 2024.","partners":"Bristol Myers Squibb","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Clinical Trial","Pancreatic Cancer","Drug Development","Partnership","Patient Enrollment"],"date_of_event":"Dec. 14, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Partners","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cHkZNk4yYD9x4gbEzdQGDJiVapVavCYVZkXzh3sOLaDf1LaRjWoLcM","news_summary":"Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"unPsQsxF7TEPHXisidhERvoNUMi5xWkiU6nKAddnGMkf2konDt3jUM","date":"Nov 21, 2023","link":"https://finance.yahoo.com/news/purple-biotech-reports-third-quarter-115000048.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Trials, Financial Results","company":"Purple Biotech Ltd.","layoffs":"Not mentioned","summary":"Purple Biotech Ltd., a clinical-stage company developing first-in-class therapies for cancer, has announced its financial results for Q3 2023. The company reported that it expects to complete patient enrollment in its Phase 2 randomized CM24 pancreatic cancer study soon, ahead of schedule. The companys cash runway has been extended to the second half of 2025 through recent financing. The company also reported initial activity in its NT219 Phase 1/2 dose escalation study for head and neck cancer. The companys financial results showed an increase in research and development expenses and a decrease in selling, general and administrative expenses.","partners":"Bristol Myers Squibb","customers":"Not mentioned","investors":"Jefferies LLC","confidence":9,"key_topics":["Cancer Research","Clinical Trials","Financial Results","Investment","Partnership"],"date_of_event":"Nov. 21, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$5 million","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"LhPj9osqDYlPp36ObcIm1c2adKxBQpcJsRLJgylLvCdbRoIQDmC15A","news_summary":"Purple Biotech Reports Third Quarter 2023 Financial Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"gk0WFDWIGCGrvHF1T9VakglrTU2MpJDY0hZSWqkDagy5AaGCH92tUz","date":"Nov 2, 2023","link":"https://finance.yahoo.com/news/purple-biotech-fortifies-nt219-patent-110000231.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Patent, Cancer Treatment","company":"Purple Biotech Ltd.","layoffs":"N/A","summary":"Purple Biotech Ltd. has been granted a new patent in China for maintaining a pharmaceutical composition of NT219 in its active form. This expands the companys patent protection for NT219 in China. NT219 is being developed for the treatment of head and neck cancer, a large market opportunity in China. The new patent protects the method which prevents the conversion of NT219 from its active form to a less active form and supports maintenance of the active form during manufacturing, storage and handling until administered to the patient.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["New Patent","Cancer Treatment","China Market","NT219","Intellectual Property"],"date_of_event":"Nov. 02, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Investment"],"acquisition_amount":"N/A","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"D1o2CiB099vfEMdG0zZGqkusJCcT06LfStTNxHGYKxdTxzHka7uZcf","news_summary":"Purple Biotech Fortifies NT219 Patent Protection","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"woOFnTRmfWd5W1KFZDhe1DsUjmOyegNfXsZ5fmpxUldHRmaJFDBv0r","date":"Oct 19, 2023","link":"https://finance.yahoo.com/news/purple-biotech-announces-closing-5-195500978.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"scJJISGJ7qTIPaNzePhixIUlGwJaccAXCAfc9eTkqv1weZKVkYx9aX","news_summary":"Purple Biotech Announces Closing of $5 Million Registered Direct Offering","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"lei1hrPLxcT4FaBd9zRZSwEzLjkwQMfBzdAHaOtJnKlTbU7xd1zZtV","date":"Oct 17, 2023","link":"https://finance.yahoo.com/news/purple-biotech-announces-5-million-120000225.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"xvs11154s2xNpTaoYRtJqbI47zSiIIKIaLz9fFgCc8HL6E4mlvhFGR","news_summary":"Purple Biotech Announces $5 Million Registered Direct Offering","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"4jGnbRKT4qP52N3f48ZMRcVc62dXlKqXSSDCivuo67ApunrZHr9X1U","date":"Oct 6, 2023","link":"https://finance.yahoo.com/news/purple-biotech-reports-potential-biomarker-115000519.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Oncology, Drug Development","company":"Purple Biotech Ltd.","layoffs":"Not mentioned","summary":"Purple Biotech Ltd. has reported new biomarker data for its lead oncology drug, CM24, which is being developed to overcome tumor immune evasion and drug resistance. The data, presented at the American Association for Cancer Research Special Conference, shows that higher pre-treatment levels of tumor infiltrating lymphocytes that express CEACAM1 may be associated with longer survival in patients treated with CM24 and nivolumab. The company is now evaluating CM24 in a randomized Phase 2 study in combination with Bristol Myers Squib’s nivolumab plus standard of care chemotherapy, as a second line treatment for pancreatic ductal adenocarcinoma.","partners":"Bristol Myers Squibb","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["CM24 Drug","Biomarker Data","Pancreatic Cancer","Clinical Trials","Partnership with Bristol Myers Squibb"],"date_of_event":"Oct. 06, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"KfK0RKH1x3RxOz71tlAkWyOME3H5dSB1ftpRZj5eKXJjzRvKaYvg94","news_summary":"Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"jYGtN0VldtTLsyx00edf62eSicY0KKsqjLSHbAtCgfZIpvTZAyJPIK","date":"Oct 3, 2023","link":"https://finance.yahoo.com/news/purple-biotech-reports-positive-interim-115000996.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Trials, Drug Development","company":"Purple Biotech Ltd.","layoffs":"Not mentioned","summary":"Purple Biotech Ltd. has reported positive results from its dose escalation portion of the Phase 1/2 study of NT219, a first in class dual inhibitor of Insulin receptor substrate (IRS) 1/2 and Signal Transducer and Activator of Transcription 3 (STAT3). The study is designed to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of NT219 as a monotherapy and in combination with Erbitux® (cetuximab), in patients with recurrent and/or metastatic squamous cell carcinoma of the head & Neck (R/M SCCHN), or with advanced colorectal cancer. The company is now planning the next clinical development steps with NT219 for second-line treatment of patients with R/M SCCHN.","partners":"Not mentioned","customers":"Patients with R/M SCCHN, or with advanced colorectal cancer","investors":"Not mentioned","confidence":9,"key_topics":["Anti-tumor Activity","NT219","Cetuximab","Phase 2 Study","SCCHN"],"date_of_event":"Oct. 03, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Customers, Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers, Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"nhLFn3UG8PkUfzUYExkt4zwE9q6GR1r9qeaoo9L1nivtwx2LDNRgEg","news_summary":"Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5cEgonlXtNy9kll1NfIuwjuMdH2Xl63YQp05lvYDfkLVgKKZYVfg5m","date":"Sep 21, 2023","link":"https://finance.yahoo.com/news/purple-biotech-present-cm24-pancreatic-120000878.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Trials, Cancer Research","company":"Purple Biotech Ltd.","layoffs":"N/A","summary":"Purple Biotech Ltd., a clinical-stage company, announced it will present a poster at the American Association for Cancer Research (AACR) Special Conference: Pancreatic Cancer, on September 28, 2023. The poster will detail a Phase 1 Study of CM24 in Combination with Nivolumab in Patients with Advanced Pancreatic Cancer. The company is also advancing its oncology pipeline which includes NT219, CM24 and IM1240. Purple Biotech has entered into a clinical collaboration agreement with Bristol Myers Squibb for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy.","partners":"Bristol Myers Squibb","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Cancer Research","Clinical Trials","Partnership","Drug Development","Company Expansion"],"date_of_event":"Sept. 21, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Partners","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"IQU2B7pC4HJ2b4PpbzgRqRflUHbPUXWgxiMTiq8SUFUk2g9EsrI4U8","news_summary":"Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"EFQEfCSUOuOok7rPwnkbO561SQfNZKK6pF1m6tssHr1SrGox8Hxiwh","date":"Aug 22, 2023","link":"https://finance.yahoo.com/news/purple-biotech-reports-second-quarter-132900487.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Financial Results, Clinical Trials, Cancer Treatment","company":"Purple Biotech Ltd.","layoffs":"Not mentioned","summary":"Purple Biotech Ltd., a clinical-stage company developing first-in-class therapies for cancer, has announced its financial results for the second quarter and six months ended June 30, 2023. The company reported an increase in research and development expenses due to higher enrollment rate in clinical trials. However, the companys cash runway has been extended into the first half of 2025. The company is also looking forward to announcing milestones including interim data from its Phase 2 CM24 study and results from its Phase 1 NT219 dose escalation study.","partners":"Bristol Myers Squibb","customers":"Not mentioned","investors":"Jefferies LLC","confidence":9,"key_topics":"Clinical Trials, Financial Results, Cancer Treatment, Research and Development, Investment","date_of_event":"August 22, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Approximately $0.85 million","structured_issues":"Investment, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WPw1L3XsYmueUcgjIk5mjRcQx2YPB0eNkFU5r1a7D9nfW1WLuzEBbu","news_summary":"Purple Biotech Reports Second Quarter 2023 Financial Results","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"pmclOtkb5BquuDKewp3dcUpSFcKmDc6QZo9VQiLbZmU8ha9w2kaSVN","date":"Jul 11, 2023","link":"https://finance.yahoo.com/news/purple-biotech-reports-positive-results-121500242.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical Trials, Oncology","company":"Purple Biotech Ltd.","layoffs":"Not mentioned","summary":"Purple Biotech Ltd., a clinical-stage company developing first-in-class therapies, announced the completion and data maturity of its Phase 1 dose escalation study of CM24, a first-in-class anti-CEACAM1 monoclonal antibody addressing multiple tumor types. The investigational immunotherapy combination was well tolerated across all dose levels with no recorded Drug Limiting Toxicities (DLTs). The company is highly encouraged by these latest Phase 1 data and plans to provide further details from this study at an upcoming medical conference. The company is continuing the Phase 2, which is enrolling as planned across multiple sites in the U.S., Europe, and Israel, and expects to share initial Phase 2 data by the end of 2023 and topline results later in 2024.","partners":"Bristol Myers Squibb","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Immuno-Oncology","Chemotherapy-Free Regimen","Phase 2 Study","PDAC Patients","Clinical Collaboration"],"date_of_event":"July 11, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Investment, Partners","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"7rz2fL8xeq9rnlL3q4u8BTYKWaQ7lG0GJ2snALzxZguRAvznfWCcsN","news_summary":"Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"HR3DkgDKEp4KlzkzHCrk9xeJPcC9b4a0clwJhdzj7e8eVcEypNG4v3","date":"May 16, 2023","link":"https://finance.yahoo.com/news/purple-biotech-reports-first-quarter-200000344.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Acquisition, Clinical Trials, Financial Results","company":"Purple Biotech Ltd.","layoffs":"Not mentioned","summary":"Purple Biotech Ltd. has announced its financial results for Q1 2023 and its acquisition of Immunorizon Ltd. The acquisition expands Purple Biotechs pipeline with new tri-specific antibodies. The company also reported progress in its ongoing clinical programs, with data readouts expected in 2023. The companys financial results showed a decrease in R&D expenses and a decrease in net loss compared to the same period in 2022. Purple Biotech also announced the inauguration of its Scientific Advisory Board and the dosing of the first patient in the randomized arm of the Phase 2 clinical trial for CM24.","partners":"Not mentioned","customers":"Not mentioned","investors":"Jefferies LLC","confidence":9,"key_topics":["Acquisition of Immunorizon Ltd","Clinical Trials","Financial Results","Scientific Advisory Board","Pipeline Expansion"],"date_of_event":"May 16, 2023","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$380,000","structured_issues":["Acquisition","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Acquisition  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bkcsjy6PHvJXUX2lAD5lRoqYd9quP4bpXWiHNv0KHYld9HOC0CcDK7","news_summary":"Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"K3It6FbEq5PMZmEjXoccMEafuzF0EF5qhj1O4ILvrOS4AybPsVwjof","date":"Apr 25, 2023","link":"https://finance.yahoo.com/news/purple-biotech-debuts-scientific-advisory-120000532.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"ZqRvSNbg7FvuoaPhuI6ytRF2Kz7HRLGRk6zxdFQ2zwJGHUco2rA1Er","news_summary":"Purple Biotech Debuts Scientific Advisory Board","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"MAA40ifQC1MoYCC7r8PsnsjvKWzhcy6S5igruOe7M22iF5an83LnEz","date":"Apr 19, 2023","link":"https://finance.yahoo.com/news/purple-biotech-reports-preclinical-data-121500264.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"zl5Lm4SLDuyRUpbMLFoJAiBHUVu0nSJ410ZldfTDsI1pIFaVITljOV","news_summary":"Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"pwJcz5xpdwRMQNeSwppK8zSEBUaXAu6u8bT0o3QedEGyrANAPInCL1","date":"Apr 18, 2023","link":"https://finance.yahoo.com/news/purple-biotech-participate-canaccord-genuitys-110000290.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"OxOUpuSoohzePomj5eZxlyetgvpMwwjFnO4QawGMP8iICxhJkSyXOH","news_summary":"Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"P5S5BqjrSOcwsgNCryMISRykL03loDUORo2lqAoOQ3rbi6CrikXH3I","date":"Mar 24, 2023","link":"https://finance.yahoo.com/news/purple-biotech-reports-temporary-medical-110000420.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"8ueHRWT2MkXrIOncEdwL8S5RWtMkQgo9t2OPfgIWc0emIdVSqQKgP3","news_summary":"Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"r2KjEsVybYf93tsyafsxo9ecadlG3oSKQi4NCnd1VMdaPLm3RlxSuV","date":"Mar 16, 2023","link":"https://finance.yahoo.com/news/purple-biotech-reports-biomarker-data-110000813.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"GQ6BkKw3gLW6miQo3U2IUsjF6iSUyVb6C4jWKbvcAwBPQiL9Ttw6VX","news_summary":"Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"CKWtKIPzuEPFfKtCFK52emzMHIcm2KkxIBdwX9hwX74uk60e6wvi4i","date":"Feb 14, 2023","link":"https://finance.yahoo.com/news/purple-biotech-announces-first-patient-120100859.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"SlS1AK7EYYz3iExAwuT21X9VE99E9t7kCGw7ersWNNvd0HQHmUAatS","news_summary":"Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"I7qDwrPAsUiMZevte8ZPGTJdnZJCfNCWAtW0b8hw2y3rV4LAr5fT8s","date":"Feb 8, 2023","link":"https://finance.yahoo.com/news/purple-biotech-reports-fourth-quarter-121200843.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"oGVyHFZem6jftaCva0sX6Yt2wJoy0vZMdtFl5vtzvbbpCwmPyNBEN5","news_summary":"Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"1WVxbUy05KDKyVXBBmROmPAimjAsn6LBqC9sNh1Ura20MYVw6dXBZU","date":"Feb 2, 2023","link":"https://finance.yahoo.com/news/purple-biotech-expands-pipeline-first-120000897.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"o5rGuHp6M0zLkDh4WVvhYJ4uf657EhqIFSHTQFOTXX24lCg64nY316","news_summary":"Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"fNpqNjYpZQ1PURnehgZo8Knjm63tQViGIW8aDFclXifT77WWdgzU6G","date":"Jan 3, 2023","link":"https://finance.yahoo.com/news/purple-biotech-mor-research-applications-120000046.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"xd81YXEATKWETnDg2KAvU11yiyva6C8uVnFFlescJ2MmolENroKzvT","news_summary":"Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"Mz6jccapLn33B4fTBWId2QJdLBoxGP2KpoD6OhOCsck7MQSRyfqh7n","date":"Nov 15, 2022","link":"https://finance.yahoo.com/news/purple-biotech-presents-data-mechanism-120000202.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"UrRsZgHDnhKjc9AolcKJEAEkfrrZCZMAQXHFq1XFc4KGNMafjDmRyZ","news_summary":"Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"e2oUTTrHhbeehicE9r8CvE4RQd42A64daQfk3IwaPak7WnxjKO64D8","date":"Nov 10, 2022","link":"https://finance.yahoo.com/news/purple-biotech-present-jefferies-london-120000793.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"VGjV4pgmRbeZSuX6FvaCOo9k0h1wVPK8eLgb7bNPKgoUZ7OZKV5Scw","news_summary":"Purple Biotech to Present at the Jefferies London Healthcare Conference","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"kfijKB5D2UlMU13IMEUEIiVjeLHGZnyjBtU2zsaC4BhRsktRFMdSYd","date":"Nov 8, 2022","link":"https://finance.yahoo.com/news/purple-biotech-reports-third-quarter-125300303.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"a54m1HLRJYpcfVeoFDCRyEXpqqwSlT5glXSu4bZ3crEwD6Duym9dqt","news_summary":"Purple Biotech Reports Third Quarter 2022 Financial Results","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"HtyFWaoNtXLi7icgQ23kgb64af9XgZ8brhRwKcw93o1tzgY7Dr7ZLl","date":"Nov 2, 2022","link":"https://finance.yahoo.com/news/purple-biotech-appoints-lior-fhima-113700913.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"XCxjGA3tBim3AIr9ozcl4G4hWq086RkHNumKDrbzMMJusHRrxTkfn8","news_summary":"Purple Biotech Appoints Lior Fhima as Chief Financial Officer","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"gMHSyBCUaaxmjbXqhyLopXuKTG5FPvLKKE4Zkv8Z3sF8JlK3EVG7Nd","date":"Aug 4, 2022","link":"https://finance.yahoo.com/news/purple-biotech-reports-second-quarter-113000385.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"jQU2BjZcXiA9bIquHJ20lbETBHHX8ycvchrR2Z7PK2twkVgQJVGKfA","news_summary":"Purple Biotech Reports Second Quarter 2022 Financial Results","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"z0eiv8PlRIhvCsIgaLtNYtUPTFzMhN0TeDdfwbxjztPBX6z1s6bebC","date":"Jul 14, 2022","link":"https://finance.yahoo.com/news/purple-biotech-announces-executive-leadership-113000919.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"management changes","company":"Purple Biotech Ltd.","layoffs":null,"summary":"Purple Biotech Ltd. has announced that Gil Efron will assume the role of Chief Executive Officer following the decision by Isaac Israel to step down from his CEO role. Israel will continue to be involved with the company as an advisor and a member of the Board of Directors. Efron has served as President and CFO of Purple Biotech since June 2021. The company is focused on developing first-in-class therapies for cancer treatment. Purple Biotechs oncology pipeline includes NT219 and CM24, which are being developed as monotherapy and combination therapies for various cancer indications. The company aims to achieve meaningful clinical results and long-term success and growth under Efrons leadership.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Gil Efron","Isaac Israel","Chief Executive Officer","Board of Directors","Oncology Pipeline"],"date_of_event":"2022-07-10","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"f7iSC4PZWonEVUWCy3Bhhq72hihmnqsy8aiiPSbi0bXfHuyZ74HqSQ","news_summary":"Purple Biotech Announces Executive Leadership Changes","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a2d94fb4-0c93-4ca5-9e93-28240681b0e0","date":"Dec 10, 2020","link":"https://www.globenewswire.com/news-release/2020/12/10/2143062/0/en/Kitov-Announces-Name-Change-to-Purple-Biotech-Ltd.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"name change","company":"Kitov Pharma Ltd.","layoffs":null,"summary":"Kitov Pharma Ltd., a clinical-stage company advancing first-in-class therapies, has changed its corporate name to Purple Biotech Ltd. The name change reflects the companys evolution and focus on advancing oncology therapies. The company has recently initiated clinical studies for NT219 and expects to begin studies for CM24. It has also completed over $60 million in financings to support its clinical development and strategic plans. The company will be relocating its corporate headquarters to the Science Park near the Weizmann Institute in Rehovot, Israel. The name change will be effective on December 22, 2020, and the companys shares will trade under the new ticker symbol, PPBT, on the TASE and NASDAQ.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["name change","oncology therapies","clinical studies","financings","relocation"],"date_of_event":"2020-12-22","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WViIgWc9ne8gYSe1qQa5e8dl6AKqYvBZY3T50hETwLPx6mDpd4D1eQ","news_summary":"Kitov Announces Name Change to Purple Biotech Ltd.","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"fccd13bb-9366-4fbc-9417-b8926aa72f53","date":"Nov 9, 2020","link":"http://www.globenewswire.com/news-release/2020/11/09/2122659/0/en/Kitov-Expands-Planned-Phase-1-2-Clinical-Trial-of-CM24-in-Non-Small-Cell-Lung-Cancer-with-New-Cohort-to-Evaluate-CM24-in-Patients-with-Pancreatic-Cancer-Conducted-with-Bristol-Myer.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"clinical trial collaboration, expansion, drug combination","company":"Kitov Pharma Ltd.","layoffs":null,"summary":"Kitov Pharma has announced an expansion of its planned Phase 1/2 clinical trial to evaluate CM24 in patients with pancreatic cancer. The trial will evaluate CM24, a monoclonal antibody targeting CEACAM1, in combination with nivolumab (Opdivo) and nab-paclitaxel (Abraxane). In an initial Phase 1 study, CM24 was found to be safe and well-tolerated. The Phase 1/2 trial will start before the end of 2020, with top-line Phase 1 results expected in the second half of 2021. The collaboration with Bristol Myers Squibb allows Kitov to design a clinical study that reflects current data in non-small cell lung cancer and pancreatic cancer. Kitov is focused on advancing CM24 as a potential first-in-class anti-CEACAM1 therapy.","partners":"Bristol Myers Squibb","customers":null,"investors":null,"confidence":8,"key_topics":["CM24","Opdivo","Abraxane","pancreatic cancer","Phase 1/2 clinical trial"],"date_of_event":"2020-11-09","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xSuDKOR5We9D7iOlbWBtaHQUoqwaAqeKAO0JuWXfqbage3OLUT7lF1","news_summary":"Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"15724c48-176e-4288-bcd0-c6fa5a1b50dc","date":"Oct 27, 2020","link":"https://www.globenewswire.com/news-release/2020/10/27/2115084/0/en/Kitov-Pharma-Receives-Notice-of-Allowance-for-a-U-S-Patent-Covering-its-Anti-Cancer-Drug-Candidate-NT219.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":["patent","clinical-stage company","therapies","tumor immune evasion","drug resistance","NT219","oncogenic drivers","hard-to-treat cancers","EGFR inhibitors","osimertinib","synergistic effect","tumor growth","clinical trials","Phase 1/2 trial","Phase 1/2 study","monotherapy treatment","combination therapy","CM24","CEACAM1","immune checkpoint","Consensi","osteaoarthritis pain","hypertension"],"company":"Kitov Pharma Ltd.","layoffs":null,"summary":"Kitov Pharma has received a Notice of Allowance from the USPTO for a patent application covering the combinations of NT219 with multiple EGFR inhibitors, including osimertinib. NT219 is a dual inhibitor that targets IRS1/2 and STAT3, important oncogenic drivers and drug resistance pathways in hard-to-treat cancers. In in-vitro studies, NT219 was shown to downregulate IRS1 and STAT3 and synergize with osimertinib in suppressing cell proliferation. In preclinical studies, NT219 demonstrated significant single-agent activity and a synergistic effect when combined with osimertinib, resulting in strong inhibition of tumor growth. Kitov plans to explore NT219 in future clinical trials. The company expects top-line data readout from its Phase 1/2 trial with NT219 in the second half of 2021.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["patent","NT219","EGFR inhibitors","osimertinib","clinical trials"],"date_of_event":"October 27, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xBMERXaPJ4VLdYKzUpouNVu2KrkEkn7oEZvFzzYBH0zCv4eCuPpz6F","news_summary":"Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"f8b0e139-cabb-42ae-84e4-d315945ce4d7","date":"Sep 8, 2020","link":"https://www.globenewswire.com/news-release/2020/09/08/2089945/0/en/Kitov-Announces-Dosing-of-First-Patient-in-Phase-1-2-Clinical-Trial-of-NT219-in-Advanced-Cancer-Patients.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"clinical trial","company":"Kitov Pharma Ltd.","layoffs":null,"summary":"Kitov Pharma has announced the dosing of the first patient in the Phase 1/2 clinical trial of NT219, a dual inhibitor targeting IRS1/2 and STAT3. The trial aims to evaluate the safety, pharmacokinetics, and efficacy of NT219 as a monotherapy and in combination with cetuximab for the treatment of advanced solid tumors, recurrent and/or metastatic solid tumors, head and neck cancer, and colorectal adenocarcinoma. Kitov expects to complete enrollment in the first part of the study and release top line data in the second half of 2021. The company is focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Phase 1/2 clinical trial","NT219","oncogenic drivers","drug resistance pathways","hard-to-treat cancers"],"date_of_event":"2020-09-08","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"CYmsOd83uJOB6y16ALuCW3cxTFW1mw3IplTqQhdJfXZhAmfdkS7r95","news_summary":"Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e3b79ae8-5d52-42f1-adcd-3add594d0409","date":"Sep 4, 2020","link":"https://www.globenewswire.com/news-release/2020/09/04/2089073/0/en/Kitov-Pharma-Receives-Notice-of-Intention-to-Grant-Two-Patents-in-China-Covering-Company-s-Lead-Oncology-Assets-CM24-and-NT219.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":["patent","oncology","China","intellectual property","clinical trial"],"company":"Kitov Pharma Ltd.","layoffs":null,"summary":"Kitov Pharma has received notification from the Chinese Patent Office granting two separate patents for its lead oncology product candidates, CM24 and NT219. The patents cover the humanized antibodies capable of specific binding to human CEACAM1 molecules and the various combinations of NT219 with multiple EGFR inhibitors. The patents extend Kitovs patent coverage to the U.S., EU, China, and multiple other countries. The company sees China as a key target market and an opportunity for potential collaboration partners. Kitov is currently preparing for a Phase 1/2 clinical trial of CM24 in combination with nivolumab and in combination with nab-paclitaxel. They are also conducting a Phase 1/2 trial evaluating NT219 as a monotherapy treatment and in combination with cetuximab. Preliminary data from the NT219 trial is expected in the second half of 2021.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["patent coverage","oncology product candidates","Chinese market","clinical trials","intellectual property"],"date_of_event":"September 4, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WuLvopCLgfD8U0vI4h4Hn3OHOUagxHED7H6jjGJX8TfsbzoXjchn0Y","news_summary":"Kitov Pharma Receives Notice of Intention to Grant Two Patents in China Covering Company's Lead Oncology Assets, CM24 and NT219","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"383ad970-c79c-47c5-ae04-5ac90af685d3","date":"Jul 8, 2020","link":"http://www.globenewswire.com/news-release/2020/07/08/2059185/0/en/Kitov-Pharma-Receives-Notice-of-Intention-to-Grant-a-European-Patent-Covering-CM24-its-anti-CEACAM1-Antibody.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"patent","company":"Kitov Pharma Ltd.","layoffs":null,"summary":"Kitov Pharma has received a patent for its application entitled Humanized antibodies against CEACAM1 from the European Patent Office. The patent covers protein and DNA sequences related to humanized antibodies capable of binding to human CEACAM1 molecules, including its lead monoclonal antibody, CM24. Kitov is preparing to initiate a Phase 1/2 clinical trial of CM24 in combination with nivolumab in lung and pancreatic cancer patients. The trial will be conducted under a clinical collaboration agreement with Bristol-Myers Squibb. The patent grant strengthens Kitovs position in developing unique cancer treatments.","partners":"Bristol-Myers Squibb","customers":null,"investors":null,"confidence":8,"key_topics":["patent","clinical trial","cancer treatment","Phase 1/2","Bristol-Myers Squibb"],"date_of_event":"2020-07-08","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"aN6gtY10eztUNHPqMGnETUmguFXAVNG6Iw6gvTM6MyTdG0zmmX4s32","news_summary":"Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6e29e0e8-f148-46cd-b365-ade3e8a86c7d","date":"Jun 23, 2020","link":"https://www.globenewswire.com/news-release/2020/06/23/2052250/0/en/Kitov-Announces-35-0-Million-Registered-Direct-Offering.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":["investment"],"company":"Kitov Pharma Ltd.","layoffs":null,"summary":"Kitov Pharma has entered into definitive agreements with healthcare-focused institutional investors for the purchase and sale of its ordinary shares and warrants in a registered direct offering. The offering is expected to raise approximately $35.0 million in gross proceeds, which will be used to fund the development of its oncology drug candidates, acquire new assets, and for general working capital purposes. The offering is set to close on or about June 25, 2020.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["clinical-stage company","definitive agreements","healthcare-focused institutional investors","registered direct offering","oncology drug candidates"],"date_of_event":"June 25, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$35.0 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"pb0DvZNVJSHPxWA9aL8lOuwW3yDKRN7ytNPXtMbaFKsbrQraKbsv15","news_summary":"Kitov Announces $35.0 Million Registered Direct Offering","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6cc3674d-5bc4-4b83-a7de-513de66ec2ae","date":"May 22, 2020","link":"https://www.globenewswire.com/news-release/2020/05/22/2037517/0/en/Kitov-Announces-U-S-FDA-Acceptance-of-Investigational-New-Drug-Application-to-Conduct-Phase-1-2-Clinical-Trial-of-NT219-in-Multiple-Types-of-Advanced-Cancer-Patients.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"clinical trial","company":"Kitov Pharma Ltd.","layoffs":null,"summary":"Kitov Pharma has announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to conduct a Phase 1/2 clinical trial of NT219, a novel agent addressing treatment resistance in advanced cancer. The study will evaluate NT219 as a monotherapy treatment for advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic solid tumors and head and neck cancer or colorectal adenocarcinoma. The primary objectives of the trial are to evaluate safety, assess pharmacokinetics, identify the appropriate dose, and establish preliminary efficacy of NT219. Kitov Pharma believes that NT219 has the potential to be a safe and effective therapy for multiple treatment-resistant cancers.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["NT219","clinical trial","treatment resistance","solid tumors","cetuximab"],"date_of_event":"2020-05-22","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ib2P6MIsklIAq3lrFdqedv0b4KTFROMxSxLrZ1eVXU4qJVIP710CQa","news_summary":"Kitov Announces U.S. FDA Acceptance of Investigational New Drug Application to Conduct Phase 1/2 Clinical Trial of NT219 in Multiple Types of Advanced Cancer Patients","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"982c936d-8896-4ec0-baf6-1a026a71fab5","date":"May 20, 2020","link":"https://www.globenewswire.com/news-release/2020/05/20/2036300/0/en/Kitov-Announces-U-S-Commercial-Launch-of-Consensi.html#:~:text=(%E2%80%9CKitov%E2%80%9D)%20(NASDAQ,the%20simultaneous%20treatment%20of%20hypertension","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Product Launch, Investment","company":"Kitov Pharma Ltd.","layoffs":"Not mentioned","summary":"Kitov Pharma Ltd. has announced the U.S. commercial launch of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, designed for the simultaneous treatment of hypertension and osteoarthritis pain. Consensi is being sold in the U.S. by Burke Therapeutics, the marketing partner of Kitov’s U.S. distributor, Coeptis Pharmaceuticals. The initial U.S. sales of Consensi represents a key milestone for Kitov. The company has also secured $26 million gross fundraising proceeds this year, which will provide financial support for their development efforts aimed at advancing their emerging oncology pipeline.","partners":["Burke Therapeutics","Coeptis Pharmaceuticals"],"customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Product Launch","Investment","Partnership","Oncology Pipeline","Market Potential"],"date_of_event":"May 20, 2020","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$26 million","structured_issues":["Customers","Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"C6Imh5OVX4yCa0PUnXUcbMbkdxawp7bgDc1HCcZjTtbkwqrJNOIc35","news_summary":"Kitov Announces U.S. Commercial Launch of Consensi™","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"48e1ffb1-9c99-4f16-b40b-963148c39a4a","date":"May 19, 2020","link":"https://www.globenewswire.com/news-release/2020/05/19/2035626/0/en/Kitov-to-Present-Preclinical-Data-on-NT219-at-American-Association-of-Cancer-Research-Virtual-Annual-Meeting-II.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"clinical-stage company, cancer treatment","company":"Kitov Pharma Ltd.","layoffs":null,"summary":"Kitov Pharma announced that preclinical data for NT219, a novel agent addressing treatment resistance in advanced cancer, will be presented at the American Association of Cancer Research (AACR) Virtual Meeting II. The data shows that NT219 demonstrated growth inhibition in multiple patient derived xenograft (PDX) models of head and neck squamous cell carcinoma (HNSCC), both as monotherapy and in combination with other inhibitors. Based on these promising results, Kitov plans to initiate a Phase 1/2 trial of NT219 as a monotherapy treatment for advanced solid tumors and in combination with cetuximab for HNSCC. The trial is expected to start soon.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["NT-219","cancer treatment","preclinical data","Phase 1/2 trial","tumor resistance"],"date_of_event":"2020-05-19","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0XeUTYxEIo6FjxF1OSTemVUTxyKI55RyKHdLkqvjEqhMKKDO7t4HZH","news_summary":"Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting II","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d74c9e3b-d566-4b2e-97a1-d2530ecd82f0","date":"Apr 20, 2020","link":"https://www.globenewswire.com/news-release/2020/04/20/2018580/0/en/Kitov-Pharma-Ltd-Announces-Cash-Proceeds-of-6-5-Million-from-Exercise-of-Warrants.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"fundraising","company":"Kitov Pharma Ltd.","layoffs":null,"summary":"Kitov Pharma has announced a transaction resulting in expected gross cash proceeds of approximately $6.5 million through the exercise of existing warrants. The company intends to use the net proceeds to fund the development of its oncology therapeutic candidates and for general working capital purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["fundraising","clinical-stage company","oncology therapeutic candidates","private placement","registration statement"],"date_of_event":"April 20, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$6.5 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WVE0DrbUkJuKz7ljJAMDyBx5CZRc1O6j6MGfqnc9k3XozbGSb6V0ZY","news_summary":"Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of Warrants","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"06840cf2-ad5c-468c-8ce3-19019be28db8","date":"Mar 12, 2020","link":"http://www.globenewswire.com/news-release/2020/03/12/1999465/0/en/Kitov-Pharma-Provides-Update-on-Planned-U-S-Launch-of-Consensi-and-Provides-Three-Year-Revenue-Forecast.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Partnership, Revenue, Drug Launch","company":"Kitov Pharma Ltd.","layoffs":"N/A","summary":"Kitov Pharma Ltd. has announced plans to commence selling its drug, Consensi, in the U.S. in May 2020. The drug, a combination of celecoxib and amlodipine besylate, is designed for the simultaneous treatment of osteoarthritis pain and hypertension. The companys manufacturing partner is completing the packaging, release, and shipment of Consensi to Kitovs marketing partners. Kitov expects to receive between $28 million and $36 million in milestone and royalty revenues from 2020 through 2022. The projected revenues will provide financial support for Kitov as it continues to advance its oncology pipeline.","partners":"Bristol Myers Squibb","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Drug Launch","Revenue Projection","Partnership","Oncology Pipeline","FDA Approval"],"date_of_event":"March 12, 2020","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Partners","Expand"],"acquisition_amount":"N/A","structuredIssuesShow":"#Partners  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"dOskW1cfxg4J18jWjPWFQcInkWTmduiLDDfNsSDXK4ca5wg29dDO3w","news_summary":"Kitov Pharma Provides Update on Planned U.S. Launch of Consensi™ and Provides Three-Year Revenue Forecast","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6194bd3b-8622-4bd3-8224-5db418bae7e2","date":"Feb 24, 2020","link":"http://www.globenewswire.com/news-release/2020/02/24/1989293/0/en/Kitov-Pharma-Expands-Planned-NT-219-Clinical-Program-for-Difficult-to-Treat-Cancers.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"clinical trial","company":"Kitov Pharma Ltd.","layoffs":null,"summary":"Kitov Pharma announced plans to expand its Phase 1/2 clinical trial of NT-219 with cetuximab to include evaluation of NT-219 as a monotherapy treatment for advanced solid tumors. The company expects to initiate the study in the second quarter of 2020 pending clearance from the FDA. NT-219 is a small molecule dual inhibitor of IRS1/2 and STAT3, pathways associated with treatment resistance. The Phase 1/2 trial will assess plasma pharmacokinetics, safety, tolerability, and maximum tolerated dose of NT-219 as a single agent and in combination with cetuximab. Kitov will present the details of the trial and new preclinical data demonstrating the anti-tumor activity of NT-219 at the 2020 Multidisciplinary Head and Neck Cancers Symposium. The expansion of the trial is based on promising preclinical data and aims to establish safety and potential efficacy of NT-219 in different clinical settings.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Phase 1/2 Study","NT-219","Cetuximab","Solid Tumors","Head and Neck Cancer"],"date_of_event":"2020-02-24","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"tX5HjfVia8Gf78djNcS5kwVIc5cKZjxfIpSiqBRRuO8lD9XU8XYDDH","news_summary":"Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e687f27c-9533-46a6-9e40-8a54cdfd07ba","date":"Feb 3, 2020","link":"https://www.globenewswire.com/news-release/2020/02/03/1978707/0/en/Kitov-Pharma-Receives-Issue-Notification-for-a-U-S-Patent-Covering-its-anti-CEACAM1-Cancer-Drug-CM-24.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"patent","company":"Kitov Pharma Ltd.","layoffs":null,"summary":"Kitov Pharma has received a patent from the USPTO for its first-in-class monoclonal antibody, CM-24. The patent provides coverage until 2035 and strengthens the companys IP portfolio. CM-24 is a clinical-stage antibody that blocks CEACAM1, a target highly expressed in solid tumors. The antibody has shown safety and efficacy in a phase 1 study, and Kitov plans to advance it as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer. The company has entered into a clinical collaboration agreement with Bristol Myers Squibb Company for the planned phase 1/2 clinical trials. Kitov expects to initiate the clinical trial in the second half of 2020.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["patent","CM-24","clinical trial","CEACAM1","combination therapy"],"date_of_event":"2020-02-03","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Ema6AhbvXRqYeyU8FJ3gr4a0WpYq4oPHiba4I7cRKV4pAKRct5wVyP","news_summary":"Kitov Pharma Receives Issue Notification for a U.S. Patent Covering its anti-CEACAM1 Cancer Drug, CM-24","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"98bef4ff-34c3-4551-9e4d-0c1deb8ae957","date":"Jan 24, 2020","link":"https://www.benzinga.com/pressreleases/20/01/g15179643/kitov-pharma-receives-notice-of-intention-to-grant-european-patent-covering-the-use-of-nt-219-in-c","source":"www.benzinga.com","visible":1,"analysis":{"tags":["patent","drug development","clinical-stage company"],"company":"Kitov Pharma Ltd.","layoffs":null,"summary":"Kitov Pharma has received a Notice of Intention to Grant for its patent application from the European Patent Office. The patent covers the treatment of NT-219, the companys dual inhibitor of IRS 1/2 and STAT3, in combination with EGFR antibodies and inhibitors. Kitov plans to initiate a phase 1/2 study in the second quarter of 2020. The company believes that the combination of NT-219 with cetuximab, an EGFR antibody, has the potential to address the unmet medical need for recurrent and metastatic Head and Neck cancer patients. Kitov Pharma is a clinical-stage company focusing on advancing therapies to overcome tumor immune evasion and drug resistance.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["patent","drug resistance","clinical trials","combination therapy","head and neck cancer"],"date_of_event":"January 24, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"upOHWFU9d8WB3Ku9A1kFxhh6aZq9Ga5idETxc8naReVZx4aytxrwEp","news_summary":"Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors - Benzinga","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"636701aa-1624-4c98-b9d0-47bb0ff4a15e","date":"Apr 12, 2019","link":"https://www.globenewswire.com/news-release/2019/04/12/1803374/0/en/Kitov-Announces-Key-Milestone-in-FameWave-Acquisition.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"acquisition","company":"Kitov Pharma Ltd.","layoffs":"","summary":"Kitov Pharma announces a key milestone in the acquisition of FameWave Ltd. The company has signed a clinical collaboration agreement with Bristol Myers Squibb for their planned Phase 1/2 clinical trials. The trials will evaluate the combination of CM-24, a monoclonal antibody, with nivolumab, a PD-1 inhibitor, in patients with non-small cell lung cancer. Kitov plans to explore higher doses of CM-24 based on preclinical studies that have shown a strong anti-cancer effect. The acquisition of FameWave is pending completion of certain closing conditions. Kitov Pharma is an innovative pharmaceutical company developing combination oncology therapies.","partners":"Bristol Myers Squibb","customers":"","investors":"","confidence":8,"key_topics":["acquisition","clinical collaboration","oncology therapies","CM-24","non-small cell lung cancer"],"date_of_event":"April 12, 2019","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"","structured_issues":["Acquisition"],"acquisition_amount":"","structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"KgX5wb6HGdoEHwBI4Ep7PTKFftkGNIU9287ewZ8CVa8Sx6yYjjPSFA","news_summary":"Kitov Announces Key Milestone in FameWave Acquisition","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"df9b5fb1-ec60-440f-a1a7-6e5e199a9ca0","date":"Mar 14, 2019","link":"https://www.globenewswire.com/news-release/2019/03/14/1753238/0/en/Kitov-to-Acquire-Clinical-Stage-Candidate-CM-24-Creating-a-Transformational-Immuno-Oncology-Company.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Acquisition, Investment","company":"Kitov Pharma","layoffs":"Not mentioned","summary":"Kitov Pharma has announced its acquisition of FameWave Ltd., a biopharmaceutical company developing CM-24, a clinical stage monoclonal antibody targeting CEACAM1, a novel immune checkpoint. The acquisition will add an immune oncology candidate to Kitov’s pipeline. As part of the agreement, Orbimed, Pontifax, and Arkin Holdings will invest $3.5 million in Kitov. Kitov plans to initiate a Phase I/II study with CM-24 in early 2020. The transaction has been approved by the boards of Kitov and FameWave and is expected to close during the third quarter of 2019.","partners":"FameWave Ltd.","customers":"Not mentioned","investors":["Orbimed","Pontifax","Arkin Holdings"],"confidence":9,"key_topics":["Acquisition","Investment","Clinical Trials","Oncology","Pharmaceuticals"],"date_of_event":"March 14, 2019","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$3.5 million","structured_issues":"Acquisition, Investment","acquisition_amount":"$10 million","structuredIssuesShow":"#Acquisition, Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"IEexlI6NVoIVFw3uY6uPmCjjkCuVejUd8urHlEhaXEGXn5Iy0p2c7h","news_summary":"Kitov to Acquire Clinical Stage Candidate CM-24 Creating a Transformational Immuno-Oncology Company","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ac48ae57-bf2a-4488-8eb4-ca4818801434","date":"Jan 17, 2019","link":"https://en.globes.co.il/en/article-kitov-raises-6m-after-positive-cancer-drug-data-1001269397#utm_source=RSS","source":"en.globes.co.il","visible":1,"analysis":{"tags":"drug development","company":"Kitov Pharma Ltd.","layoffs":null,"summary":"Israeli biopharmaceutical company Kitov Pharma is raising $6 million in a private placement with institutional investors. The companys share price rose 170% following the publication of data showing the effectiveness of its NT219 drug in shutting down cancer pathways. However, the share price fell 42% after the announcement of the private placement. The investment will contribute to the companys growth.","partners":null,"customers":null,"investors":"institutional investors","confidence":8,"key_topics":["NT219 drug","private placement","share price","cancer pathways","anti-cancer effect"],"date_of_event":"January 17, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$6 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"oUgEBOvClqMtaBWrhvgtoGybN13Xv07p4p7zvFCvb6oBLXLnlmZIbN","news_summary":"Kitov raises $6m after positive cancer drug data","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0b2c204c-2368-45ad-8053-b482e325cef1","date":"Jan 15, 2019","link":"https://www.globenewswire.com/news-release/2019/01/15/1691707/0/en/New-Data-on-Kitov-s-NT219-Demonstrates-its-Unique-Mechanism-of-Action-and-Anti-Cancer-Effect.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Pharmaceuticals, Cancer Research","company":"Kitov Pharma Ltd.","layoffs":"Not mentioned","summary":"Kitov Pharma has announced new findings from its ongoing collaboration with researchers from the Hebrew University of Jerusalem. The data shows that NT219, a first-in-class drug candidate, has high affinity and selective binding to its target proteins, which are known modulators of tumor survival, metastasis and drug resistance. A short exposure of cancerous cells to NT219 was sufficient to trigger irreversible shutdown of these pathways, resulting in a long-term anti-cancer effect. Kitov and Yissum, the Technology Transfer company of the Hebrew University of Jerusalem, have extended their collaboration agreement to further understand NT219’s efficacy in overcoming tumors’ resistance to immunotherapy.","partners":"Hebrew University, Yissum","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Cancer Drug","Research Collaboration","Drug Resistance","Clinical Trials","Investment"],"date_of_event":"January 15, 2019","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"okXuKh3CfsOujvRFUjTanHmgXiW1wHZTIaAcS1vfY8sy5qrlm2XSzF","news_summary":"New Data on Kitov's NT219 Demonstrates its Unique Mechanism of Action and Anti-Cancer Effect","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"79e63544-cdb3-4d24-a968-56fb80e39f0d","date":"Jan 7, 2019","link":"https://seekingalpha.com/article/4231803-kitov-secures-consensi-commercial-deal-coeptis","source":"seekingalpha.com","visible":1,"analysis":{"tags":"Partnership, Drug Commercialization","company":"Kitov Pharmaceuticals","layoffs":"Not mentioned","summary":"Kitov Pharmaceuticals has signed an exclusive marketing and distribution agreement with Coeptis Pharmaceuticals for the U.S. commercialization of Kitovs FDA approved combination drug Consensi. The terms of the deal are favorable for Kitov, with Coeptis providing an initial milestone payment of $3.5M, with additional milestone payments upon the completion of an agreed CMC plan, and upon the first sale of Consensi in the U.S. In addition to milestone payments, Kitov will split net profits with Coeptis, 40-60%, on the sales of Consensi in the U.S.","partners":"Coeptis Pharmaceuticals","customers":"Not mentioned","investors":"Coeptis Pharmaceuticals","confidence":9,"key_topics":["Partnership Agreement","Drug Commercialization","Investment","Pharmaceutical Industry","Drug Development"],"date_of_event":"January 3, 2019","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$3.5M","structured_issues":["Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8LokcdIvdq2Yk4NjS3dqVFuvrgYSylsk67ZXRCxBZ5BbhddbbR727D","news_summary":"Kitov Secures Consensi Commercial Deal With Coeptis (NASDAQ:KTOV)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5d8071ad-2f3a-48bc-9d27-14ce65558189","date":"Oct 11, 2018","link":"https://www.globenewswire.com/news-release/2018/10/11/1619923/0/en/Kitov-Appoints-Gil-Efron-as-Deputy-Chief-Executive-Officer-and-Chief-Financial-Officer.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"management changes","company":"Kitov Pharma Ltd.","layoffs":null,"summary":"Kitov Pharma has announced the retirement of Simcha Rock as CFO and the appointment of Gil Efron as the new Deputy CEO and CFO. Rock will continue to serve on the companys Board of Directors and as a strategic advisor. Efron brings over 25 years of experience in public company and financial management positions. Kitov Pharma is an innovative biopharmaceutical drug development group of companies, and with the recent FDA approval of its lead drug, Consensi™, the company is well positioned for growth. The transition of responsibilities between Rock and Efron is planned to be completed by year-end.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["CFO retirement","New CFO appointment","Leadership transition","Company growth","Drug development"],"date_of_event":"2018-10-11","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bJWgs9trqpzPqPKNn10WZeiIFGqKNB8nG9CGBtwIMKO52szdVQ9wu8","news_summary":"Kitov Appoints Gil Efron as Deputy Chief Executive Officer and Chief Financial Officer","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"78299a30-3700-4d24-a168-6ccd2a7aa99f","date":"Jan 3, 2018","link":"http://en.globes.co.il/en/article-kitov-pharmaceuticals-soars-on-us-distribution-agreement-1001267679","source":"en.globes.co.il","visible":1,"analysis":{"tags":"exclusive agreement","company":"Kitov Pharmaceuticals","layoffs":null,"summary":"Kitov Pharmaceuticals has signed an exclusive agreement with Coeptis Pharmaceuticals to commercialize its drug Consensi, designed to treat osteoarthritis pain and hypertension simultaneously. The agreement provides for total milestone payments from Coeptis to Kitov of $3.5 million, and Kitov will receive 40%-60% of Coeptis net profit on Consensi sales. Consensi, under patent protection in the US until 2030, is expected to be launched in 2019. Kitovs CEO believes that the successful commercialization of Consensi in the US will be a transformational value-creating event for the company.","partners":["Coeptis Pharmaceuticals"],"customers":null,"investors":null,"confidence":9,"key_topics":["exclusive agreement","Consensi","osteoarthritis pain","hypertension","commercialization"],"date_of_event":"January 3, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"7iVWbQnHxKRS7vETRKBPwEdsg6NqVmRFKQhbVCvOFo428AMMYog57E","news_summary":"Kitov Pharmaceuticals soars on US distribution agreement","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ff67eeeb-7225-4361-ac09-190e584a7111","date":"Oct 15, 2017","link":"http://kitovpharma.investorroom.com/Kitov-Pharmaceuticals-Announces-Phase-III-IV-Clinical-Trial-for-KIT-302-Successfully-Meets-Primary-Endpoint-and-also-Demonstrates-Drug-Candidate-Improves-Renal-Function","source":"kitovpharma.investorroom.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"ybX0k64AfELlgLM6BBQCiYnt3SfnRcDzcd3VBHHqa6wXATUc7SMkoN","news_summary":"http://kitovpharma.investorroom.com/Kitov-Pharmaceuticals-Announces-Phase-III-IV-Clinical-Trial-for-KIT-302-Successfully-Meets-Primary-Endpoint-and-also-Demonstrates-Drug-Candidate-Improves-Renal-Function","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"e30f8af5-c6f2-47d4-a31d-d6d7848b08b5","date":"Jul 11, 2017","link":"http://www.prnewswire.com/news-releases/kitov-pharmaceuticals-announces-pricing-of-35-million-registered-direct-offering-633828713.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"investment","company":"Kitov Pharmaceuticals","layoffs":null,"summary":"Kitov Pharmaceuticals has entered into definitive agreements with investors for a registered direct offering, resulting in gross proceeds of approximately $3,526,032. The offering is expected to close on or about July 14, 2017. Kitov Pharmaceuticals is an innovative biopharmaceutical company focused on late-stage drug development.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["registered direct offering","American Depositary Shares","warrants","prospectus","drug development"],"date_of_event":"July 14, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$3,526,032","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"IVlhsnZlROB3HNVkqLnng9SmhjLnekS2OXwg8vwyhu4OjI313Ll7rj","news_summary":"Kitov Pharmaceuticals Announces Pricing of $3.5 Million Registered Direct Offering","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"90d277f0-796f-4a19-87b4-c35190daa0ac","date":"Jan 13, 2017","link":"http://www.prnewswire.com/news-releases/kitov-enters-immuno-oncology-field-through-acquisition-of-tyrnovo-610550855.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"acquisition","company":"Kitov Pharmaceuticals Holdings Ltd.","layoffs":null,"summary":"Kitov Pharmaceuticals has announced the acquisition of a majority stake in TyrNovo, a developer of novel small molecules in the immuno-oncology therapeutic field. This acquisition allows Kitov to expand its pipeline and enter the immuno-oncology market, which is projected to reach $14 billion by 2019. Kitov plans to submit a New Drug Application (NDA) for its flagship combination drug, KIT-302, in Q1 2017. The company also plans to develop NT219, TyrNovos drug candidate, as a platform combination drug for overcoming multi-drug resistance in various tumors. Kitov will initially acquire a 56% equity stake in TyrNovo for $2 million in cash and $1.8 million in Kitov shares. The acquisition is expected to close on January 13, 2017.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["immuno-oncology","drug candidate","expansion","pipeline","acquisition"],"date_of_event":"January 13, 2017","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"7FF9HQiJOZUTiFGOgPa0EPHxDDKza2UVFZYPMldok8BCe1DEzhWicm","news_summary":"Kitov Enters Immuno-Oncology Field Through Acquisition of TyrNovo","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"20aa5ffd-2364-4092-964c-74549fce1434","date":"Sep 29, 2016","link":"http://www.globes.co.il/en/article-kitov-pharma-share-up-on-trial-success-1001154946","source":"www.globes.co.il","visible":1,"analysis":{"tags":"FDA approval","company":"Kitov Pharmaceutical Holdings Ltd.","layoffs":null,"summary":"Kitov Pharmaceutical Holdings Ltd. announced that its flagship product, the KIT-302 integrated drug for pain relief and lowering blood pressure, has successfully completed another pharmacokinetic bioequivalence study and met the U.S. Food and Drug Administrations standards. The trials success brings the company one step closer to applying for a final FDA marketing approval. The share price of Kitov Pharmaceutical Holdings Ltd. has risen 8% on the Tel Aviv Stock Exchange following the announcement.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Kit-302","pharmacokinetic bioequivalence study","FDA approval","share price","market cap"],"date_of_event":"September 28, 2016","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"TK7obyp6adiH7vRL8VrLkxvyEswkIkLMebX8ZtSVqi5T4pbQUQtbdQ","news_summary":"Kitov Pharma jumps on osteoarthritis trial success","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0e070cd2-cd41-4ace-bc79-c78667e0b950","date":"Aug 10, 2016","link":"http://www.prnewswire.com/news-releases/kitov-announces-issuance-of-us-patent-securing-long-term-exclusivity-for-kit-302-ahead-of-new-drug-application-to-the-fda-589693211.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"patent","company":"Kitov Pharmaceuticals","layoffs":null,"summary":"Kitov Pharmaceuticals has been issued a patent for its lead drug candidate KIT-302, which treats pain caused by osteoarthritis and hypertension. The patent will be submitted for a New Drug Application to the U.S. Food and Drug Administration by the end of 2016. This is a significant achievement for Kitovs combination drug developments. The company is focused on late-stage drug development and has a pipeline of two combination drugs for osteoarthritis pain and hypertension. Kitov aims to maximize value to its shareholders by further developing its patent holdings over proprietary assets.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["patent","drug development","FDA","combination drugs","osteaoarthritis"],"date_of_event":"August 10, 2016","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"r3JK4sCES51eiXeDPSxu1WD1blFud8SBZYduNmnzapAylubwUtqz8b","news_summary":"Kitov Announces Issuance of U.S. Patent Securing Long-Term Exclusivity for KIT-302 Ahead of New Drug Application to the FDA","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ac191e2c-8289-44cb-804a-48729a5ff1ee","date":"Jun 29, 2016","link":"http://www.globes.co.il/en/article-kitov-pharmaceuticals-raises-12m-1001136246","source":"www.globes.co.il","visible":1,"analysis":{"tags":"drug development","company":"Kitov Pharmaceutical Holdings Ltd.","layoffs":null,"summary":"Kitov Pharmaceutical Holdings Ltd. has announced a $12 million financing round, mainly from US biomed funds. The company is developing a compound drug for the treatment of pain and hypertension. The funding will be used for additional trials and potentially to expand its product pipeline. Kitov is preparing to submit its product to the US Food and Drug Administration (FDA) by the end of the year.","partners":null,"customers":null,"investors":"US biomed funds","confidence":9,"key_topics":["compound drug","pain","hypertension","financing round","FDA submission"],"date_of_event":"June 29, 2016","valuation_amount":"$25 million","impact_on_company":"growth-positive","investment_amount":"$12 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ZApy84iCTrt1okmUSEw5TFqOy6jvUTZooocYEYyVkJjEsMEpko9wKC","news_summary":"Kitov Pharmaceuticals secondary offering raises $12m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8026a866-6b27-4e26-ae07-6915f09098d7","date":"Nov 20, 2015","link":"http://www.prnewswire.com/news-releases/kitov-pharmaceuticals-holdings-announces-pricing-of-us-initial-public-offering-and-nasdaq-listing-552301701.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"IPO","company":"Kitov Pharmaceuticals Holdings Ltd.","layoffs":null,"summary":"Kitov Pharmaceuticals Holdings Ltd. has announced the pricing of its initial public offering in the United States. The company plans to offer 3,158,900 American Depository Shares (ADSs) and warrants to purchase up to 3,158,900 ADSs. The gross proceeds from the offering are expected to be $13,046,257. The net proceeds will be used to fund the companys ongoing development plan, repay indebtedness, and for working capital and other general corporate purposes. The ADSs and warrants are scheduled to begin trading on the NASDAQ Capital Market. The offering is expected to close on or about November 25, 2015.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["IPO","pricing","proceeds","underwriters","registration statement"],"date_of_event":"November 20, 2015","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"pLTsbiLP0LuZHNXIGkncwaNL3upUyQbn0QPwFNiTwWhrw4tHa7MBiX","news_summary":"Kitov Pharmaceuticals Holdings Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"36ab1eaa-af65-4a51-9d96-3467c6c0504c","date":"Nov 8, 2015","link":"http://www.globes.co.il/en/article-kitov-pharmaceuticals-files-to-raise-125m-on-wall-st-1001079525","source":"www.globes.co.il","visible":1,"analysis":{"tags":"fundraising, American Depository Share offering, Nasdaq listing","company":"Kitov Pharmaceutical Holdings Ltd.","layoffs":null,"summary":"Kitov Pharmaceutical Holdings Ltd. has submitted a prospectus to raise up to $12.5 million on Wall Street. The company plans to offer American Depository Shares (ADS) and expects to list on the secondary Nasdaq exchange. The funds will be used for a Phase III trial of its arthritis treatment, refinancing existing debt, and developing additional products. The underwriter for the offering is Rodman & Renshaw. Kitov recently acquired Nextgen-Biomed from Dermipsor for a total value of $1.2 million. The company is expected to report initial results of the Phase III trial this year.","partners":["Dermipsor"],"customers":null,"investors":"Rodman & Renshaw","confidence":9,"key_topics":["Phase III trial","arthritis treatment","prospectus","fundraising","Nasdaq listing"],"date_of_event":"November 8, 2015","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$12.5 million","structured_issues":["Investment"],"acquisition_amount":"$1.2 million","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"WC5V0NHJh1mKlsJQfUQpILqrPbazsCgfR2aaW9eUMKzRVBpIvTrHb7","news_summary":"Kitov Pharmaceuticals files to raise $12.5m on Nasdaq","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"c1b3f3cd-7d87-43e9-aac8-d9aefec60035","date":"Jun 12, 2012","link":"http://www.globes.co.il/en/article-1000758639","source":"www.globes.co.il","visible":1,"analysis":{"tags":"acquisition","company":"Kitov Pharmaceuticals","layoffs":null,"summary":"XTL Biopharmaceuticals announced its acquisition of Kitov Pharmaceuticals for up to $48 million. Kitov develops combination drug products for the treatment of hypertension and pain induced by osteoarthritis. XTL will invest up to $1.5 million in financing Kitovs Phase III clinical trial and estimates a total investment of $9 million for the development and approval of Kitovs lead drug. Dr. Paul Waymack, founder of Kitov, will join XTLs board of directors as chairman and president. The acquisition is seen as a positive growth move for Kitov Pharmaceuticals.","partners":null,"customers":null,"investors":"XTL Biopharmaceuticals Ltd.","confidence":8,"key_topics":["acquisition","drug development","clinical trial","investment","FDA"],"date_of_event":"June 19, 2012","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":"$48 million","structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"l2yLfrkK5yp7LMVkor1bOtK7s6zxN02czYSDJD9R7GjOuQSTg1bODv","news_summary":"XTL Bio buys Kitov Pharmaceuticals for up to $48m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":114,"techcommunityinvolvement":null,"mediagallery":[],"tags":["immunotherapy","antibodies","pharmaceuticals","oncology","cancer","cancer-therapy","drug-development"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["NT-219","IM1240","CM-24"],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":8327205,"marketcapitaldate":"2025-11-01T14:05:28.000Z","funding":{"investors":2,"lastfunding":"$3.06M","totalrounds":11,"fundingstage":"Public","totalfunding":"$94.6M","publicinvestors":2,"lastpublicfunding":3060000,"totalpublicrounds":11,"totalpublicfunding":94600000},"team":[{"name":"Gil Efron","email":"gile@purple-biotech.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4OOiraQKDA","bounced":false,"claimed":0,"founder":0,"urlname":"gil-efron","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg04Ob3QoM","position":"CEO","last_name":"Efron","claimtoken":"l4sFIHjWGDBWF8hnFXWPsx5O153md7bYVtKhmTzh2CQj6O3w9bP2uA","first_name":"Gil","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/gil-efron-a797a7/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-10-22 17:08:46.000000","initials":"GE","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Hadas  Reuveni, PhD","email":"hadas@kitovpharma.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoMOgs7QIDA","bounced":true,"claimed":0,"founder":1,"urlname":"hadas-reuveni-phd","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgo-js0ggM","position":"Co-founder & VP R&D","last_name":"Reuveni, PhD","claimtoken":"WOWlrXei5TYYiVsQItlTWiyCuwL0ZljrysEkxRqjrvBlqoDMnFLIEz","first_name":"Hadas ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/hadas-reuveni-67099343/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-01-08 12:24:18.000000","initials":"HR","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Lior Fhima","email":"liorf@purple-biotech.com","phone":"","gender":"Male","userid":"O6UR4LHoZ1qZLuCSgiEG5eb92l3d8GPRJMQ6f62WEFNhomaS9c56Eg","bounced":false,"claimed":1,"founder":0,"urlname":"lior-fhima","visible":1,"memberid":"LpqMvSdtsuLMXidczvJNNtkuUp5CNHNfLodj0QQZ2Z9rnbOhRrO6LU","position":"CFO","last_name":"Fhima","claimtoken":"KrkTcvTNQ8dejl116lnj9j8o8oczNP3xTjfDoZwC4b1MEl7tbJBctX","first_name":"Lior","picturekey":null,"claimeddate":"2023-02-15","linkedinurl":"https://www.linkedin.com/in/lior-fhima/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-02-07 22:33:25.000000","initials":"LF","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Yael  Lahat","email":"yaell@purple-biotech.com","phone":"","gender":"Female","userid":"avCedBGLzRL6PFzY9PTIXose76yVSQDwVql9oAyXgM2R9cd853jf8q","bounced":false,"claimed":1,"founder":0,"urlname":"yael-rosenberg-lahat","visible":1,"memberid":"d5cumkK1d5be1GuSNMB4ptzu8rWWOf1EpovJrZMXRMRFYovs5iqZFT","position":"Director of Business Development","last_name":"Lahat","claimtoken":"bZn1vVGgUgFKOx1hl9GspXoHyrUmziix1XTW2idvGMNN67YRgM5DNX","first_name":"Yael ","picturekey":null,"claimeddate":"2023-10-18","linkedinurl":"https://www.linkedin.com/in/yael-lahat-8095bb17/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-10-17 17:56:44.000000","initials":"YL","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-05-20T00:00:00.000Z","crunchbaseid":"kitov-pharmaceuticals","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Sharon Shapira","creator_email":"shapira.sharon2@gmail.com","createdate":"2014-11-09T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"fb6EFiSkS6eN8hnAX4ihpvjbPs5Vr7ONWVCBJ56zp9fO9qGpnvgM7n","date":"Sep 2025","amount":"Undisclosed","source":"","ticker":"PPBT","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$3.06M","stockexchange":"TASE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCot526Cgw","stockexchange_logokey":"$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":3060000,"valuationnumber":null},{"id":"KWMex3dkLck3mwoq1h4zsGIpZHXJA64sSTBTpHm6Yj7yOrytxZhg51","date":"Dec 2024","amount":"$2.8M","source":"https://finance.yahoo.com/news/purple-biotech-announces-2-8-132300782.html","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2800000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"FuNxlPn8asXl6ajoi3bgOaD1MHglmiu99P4IrhYvyWpELb9hwtVGzT","date":"Sep 2024","amount":"$1.24M","source":"https://www.gurufocus.com/news/2605942/armistice-capital-llc-acquires-shares-in-purple-biotech-ltd","eventtype":"FundingRoundEvent","investment":[{"name":"Armistice Capital","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/armistice-capital","logokey":"$SPbLgAIIVUg7cY2IxLbP0BiwNeSRbIbsKiXPtjaCAT4UjwsroGuazj","tagline":"","urlname":"/investor_page/armistice-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEqKzCCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"xiyFMN6jhzpqof2CqFSL67vXBIEZbZ9bZ7ZvgsKIEXYwWESpqY7qvQ","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$SPbLgAIIVUg7cY2IxLbP0BiwNeSRbIbsKiXPtjaCAT4UjwsroGuazj","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1240000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"w8JEF7fkRBYw0XMZ3pZhxL6l3qV8xxV3yvkHTbcYscLuzw1Cer6oKN","date":"Jul 2024","amount":"$2M","source":"https://www.globenewswire.com/en/news-release/2024/07/02/2907773/0/en/Purple-Biotech-Announces-Closing-of-Exercise-of-Warrants-for-2-Million-Gross-Proceeds.html","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"4zOSqcYEKxQ1bdEzHkLpNZ6nHPDLsOz2ADnZLCyT38kGI3Jf67eIqv","date":"Oct 2023","amount":"$5M","source":"https://www.globenewswire.com/en/news-release/2023/10/17/2761448/0/en/Purple-Biotech-Announces-5-Million-Registered-Direct-Offering.html","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":null,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"MLadDIhpz60YNhrvhPbeLS7WMMh4Vokv9zEDKQaz6n6bQugSfJQrGB","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"ZRQcERKz5pC08ibM3xtBBN3Jxs6tpU6MWyYrn3y206erEu5b4ljakV","date":"Feb 2023","amount":"$100M","source":"https://www.fiercebiotech.com/biotech/purple-biotech-paint-immunorizons-tri-specific-antibodies-100m-acquisition","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Immunorizon","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkJSx6-EJDA","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/company_page/immunorizon","acquiredcompany_mna_logokey":"$ssQcjPiSvqcUmSFyHChKIXzGUZooTfyoYf4viTyllGpoYwnGo5WQhq","acquiredcompany_mna_urlname":"/company_page/immunorizon","acquiredcompany_mna_homepage":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$ssQcjPiSvqcUmSFyHChKIXzGUZooTfyoYf4viTyllGpoYwnGo5WQhq","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":100000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"6eR5hDOhEkztfSCkjCd9NoIBiN9vhhnhvsOLS2ofHbv6tFDDs7J9Ol","date":"Jun 2020","amount":"$35M","source":"https://www.globenewswire.com/news-release/2020/06/23/2052250/0/en/Kitov-Announces-35-0-Million-Registered-Direct-Offering.html","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":null,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"HgkAd4KXtl3yQphAnk0OdPyNQK7lhPEwmVG0jHD9dd1v51K4Ro70iG","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":35000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCu_oSPCgw","date":"Apr 2020","amount":"$6.5M","source":"https://www.globenewswire.com/news-release/2020/04/20/2018580/0/en/Kitov-Pharma-Ltd-Announces-Cash-Proceeds-of-6-5-Million-from-Exercise-of-Warrants.html","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":6500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODVnq_OCQw","date":"Jan 2019","amount":"Undisclosed","source":"Added by Yael Lahat","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"FameWave","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD1yPjCCww","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/famewave","acquiredcompany_mna_logokey":null,"acquiredcompany_mna_urlname":"/company_page/famewave","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"/assets/empty-state.svg","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODElf_2Cww","date":"Jan 2019","amount":"$6M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":6000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCk2v7uCQw","date":"Jan 2017","amount":"$3.8M","source":"Migrated","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"TyrNovo","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ3QjIwKDA","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/company_page/tyrnovo","acquiredcompany_mna_logokey":"$ktQmdzUgWbQ4mUBU3Np0W7THnxMoZenqmBQZS0pSBVUqUzxZIWRQxb","acquiredcompany_mna_urlname":"/company_page/tyrnovo","acquiredcompany_mna_homepage":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$ktQmdzUgWbQ4mUBU3Np0W7THnxMoZenqmBQZS0pSBVUqUzxZIWRQxb","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":3800000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCojYusCQw","date":"Nov 2015","amount":"Undisclosed","source":"https://www.sec.gov/Archives/edgar/data/1614744/000114420415068022/v425700_ex99-1.htm","ticker":"PPBT","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$13M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":13000000,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODwxKWhCAw","date":"Jul 2013","amount":"Undisclosed","source":"","ticker":"PPBT (Former KTOV)","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$10M","stockexchange":"TASE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCot526Cgw","stockexchange_logokey":"$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":10000000,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEzfzpCAw","date":"Jan 2012","amount":"$10M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"904af194-5dec-44cc-984e-f65fa6880a2d","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":10000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"AghdtoaPI6mz5lkEADCNge8d64zl8PI5eKaHNb2Z1vHyOq9iSnT6bc","hub":"Arc Innovation Center","date":"","batch":"","amount":"Undisclosed","hub_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Nzf9a0IDA","source":"","enddate":"","hub_type":"Corporate Accelerator","eventtype":"GraduationEvent","hub_hidden":false,"investment":[],"hub_fullurl":"/program_page/arc-innovation-center","hub_logokey":"$h4kVs9Y8FIw1PlL9peLoiBUHlwkeM0hVe5lCktvnAuF1BF3VW20V0c","hub_urlname":"/program_page/arc-innovation-center","eventvisibility":null,"amountvisibility":null,"fundingvisibility":null,"style":"","hiddenCompanyTooltip":"","hub_logourl":"https://storage.googleapis.com/clean-finder-353810/$h4kVs9Y8FIw1PlL9peLoiBUHlwkeM0hVe5lCktvnAuF1BF3VW20V0c","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"8/1968","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Purple Biotech","logourl":"https://storage.googleapis.com/clean-finder-353810/$25bRhdsVgwjsw5gGHwllY1Bhuh47gHfhNqXV6cabjGJHh5Ao4rQ1Dw","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$25bRhdsVgwjsw5gGHwllY1Bhuh47gHfhNqXV6cabjGJHh5Ao4rQ1Dw","seoabout":"Purple Biotech is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company’...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":4,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Cells","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Cells"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Cells"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"fb6EFiSkS6eN8hnAX4ihpvjbPs5Vr7ONWVCBJ56zp9fO9qGpnvgM7n","date":"Sep 2025","amount":"Undisclosed","source":"","ticker":"PPBT","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$3.06M","stockexchange":"TASE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCot526Cgw","stockexchange_logokey":"$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":3060000,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCojYusCQw","date":"Nov 2015","amount":"Undisclosed","source":"https://www.sec.gov/Archives/edgar/data/1614744/000114420415068022/v425700_ex99-1.htm","ticker":"PPBT","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$13M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":13000000,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODwxKWhCAw","date":"Jul 2013","amount":"Undisclosed","source":"","ticker":"PPBT (Former KTOV)","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$10M","stockexchange":"TASE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCot526Cgw","stockexchange_logokey":"$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$lbzaT2u1ZZsaxZoI8dlPGaVypdtKjf7mkYzKR0EFwkK0sKlf9u3hyJ","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":10000000,"valuationnumber":null}],"privateequityfunding":[{"id":"KWMex3dkLck3mwoq1h4zsGIpZHXJA64sSTBTpHm6Yj7yOrytxZhg51","date":"Dec 2024","amount":"$2.8M","source":"https://finance.yahoo.com/news/purple-biotech-announces-2-8-132300782.html","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2800000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"FuNxlPn8asXl6ajoi3bgOaD1MHglmiu99P4IrhYvyWpELb9hwtVGzT","date":"Sep 2024","amount":"$1.24M","source":"https://www.gurufocus.com/news/2605942/armistice-capital-llc-acquires-shares-in-purple-biotech-ltd","eventtype":"FundingRoundEvent","investment":[{"name":"Armistice Capital","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/armistice-capital","logokey":"$SPbLgAIIVUg7cY2IxLbP0BiwNeSRbIbsKiXPtjaCAT4UjwsroGuazj","tagline":"","urlname":"/investor_page/armistice-capital","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCEqKzCCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"xiyFMN6jhzpqof2CqFSL67vXBIEZbZ9bZ7ZvgsKIEXYwWESpqY7qvQ","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$SPbLgAIIVUg7cY2IxLbP0BiwNeSRbIbsKiXPtjaCAT4UjwsroGuazj","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1240000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"w8JEF7fkRBYw0XMZ3pZhxL6l3qV8xxV3yvkHTbcYscLuzw1Cer6oKN","date":"Jul 2024","amount":"$2M","source":"https://www.globenewswire.com/en/news-release/2024/07/02/2907773/0/en/Purple-Biotech-Announces-Closing-of-Exercise-of-Warrants-for-2-Million-Gross-Proceeds.html","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"4zOSqcYEKxQ1bdEzHkLpNZ6nHPDLsOz2ADnZLCyT38kGI3Jf67eIqv","date":"Oct 2023","amount":"$5M","source":"https://www.globenewswire.com/en/news-release/2023/10/17/2761448/0/en/Purple-Biotech-Announces-5-Million-Registered-Direct-Offering.html","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":null,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"MLadDIhpz60YNhrvhPbeLS7WMMh4Vokv9zEDKQaz6n6bQugSfJQrGB","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":5000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"6eR5hDOhEkztfSCkjCd9NoIBiN9vhhnhvsOLS2ofHbv6tFDDs7J9Ol","date":"Jun 2020","amount":"$35M","source":"https://www.globenewswire.com/news-release/2020/06/23/2052250/0/en/Kitov-Announces-35-0-Million-Registered-Direct-Offering.html","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":null,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"HgkAd4KXtl3yQphAnk0OdPyNQK7lhPEwmVG0jHD9dd1v51K4Ro70iG","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":35000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCu_oSPCgw","date":"Apr 2020","amount":"$6.5M","source":"https://www.globenewswire.com/news-release/2020/04/20/2018580/0/en/Kitov-Pharma-Ltd-Announces-Cash-Proceeds-of-6-5-Million-from-Exercise-of-Warrants.html","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":6500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODElf_2Cww","date":"Jan 2019","amount":"$6M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"PIPE","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":6000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEzfzpCAw","date":"Jan 2012","amount":"$10M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"904af194-5dec-44cc-984e-f65fa6880a2d","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":10000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[{"id":"ZRQcERKz5pC08ibM3xtBBN3Jxs6tpU6MWyYrn3y206erEu5b4ljakV","date":"Feb 2023","amount":"$100M","source":"https://www.fiercebiotech.com/biotech/purple-biotech-paint-immunorizons-tri-specific-antibodies-100m-acquisition","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Immunorizon","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkJSx6-EJDA","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/company_page/immunorizon","acquiredcompany_mna_logokey":"$ssQcjPiSvqcUmSFyHChKIXzGUZooTfyoYf4viTyllGpoYwnGo5WQhq","acquiredcompany_mna_urlname":"/company_page/immunorizon","acquiredcompany_mna_homepage":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$ssQcjPiSvqcUmSFyHChKIXzGUZooTfyoYf4viTyllGpoYwnGo5WQhq","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":100000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODVnq_OCQw","date":"Jan 2019","amount":"Undisclosed","source":"Added by Yael Lahat","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"FameWave","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOD1yPjCCww","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/famewave","acquiredcompany_mna_logokey":null,"acquiredcompany_mna_urlname":"/company_page/famewave","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"/assets/empty-state.svg","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCk2v7uCQw","date":"Jan 2017","amount":"$3.8M","source":"Migrated","mnatype":"Acquisition","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"TyrNovo","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ3QjIwKDA","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/company_page/tyrnovo","acquiredcompany_mna_logokey":"$ktQmdzUgWbQ4mUBU3Np0W7THnxMoZenqmBQZS0pSBVUqUzxZIWRQxb","acquiredcompany_mna_urlname":"/company_page/tyrnovo","acquiredcompany_mna_homepage":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$ktQmdzUgWbQ4mUBU3Np0W7THnxMoZenqmBQZS0pSBVUqUzxZIWRQxb","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":3800000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"others":[]}}